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Ab   antibody 
AID   autoimmune disease 
AKT   also known as PKB 
AP-1   activator protein 1 
APC   antigen-presenting cell 
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APRIL  a proliferation-inducing ligand 
BAFF   B cell-activating factor, also kown as BLyS 
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BHK cells  baby hamster kidney cells 
BLK   B lymphoid tyrosine kinase 
BLyS   B lymphocyte survival factor, also known as BAFF 
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Breg   regulatory B cell 
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CREB   cAMP response element-binding protein 
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CSNK1  casein kinase 1 
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FACS    fluorescence activated cell sorter 
FCS   foetal calf serum 
FITC   fluorescein isothiocyanate 
GzmB   granzyme B 
HRP   horse radish peroxidase 
IC50   half maximal inhibitory concentration 
 IFN   interferon 
Ig   immunoglobulin 
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MAPK  mitogen-activated protein kinase 
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mTOR   mammalian target of rapamycin 
NF-κB   nuclear factor kappa B 
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PBS   phosphate buffered saline 
PD(-L)  programmed death (-ligand) 
PC   plasma cell 
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PE/Cy5   phycoerythrin-cyanine 5 
PI3K   phosphatidylinositol-3-kinase 
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siRNA   small interference ribonucleic acid 
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SYK   spleen tyrosine kinase 
TCR   T cell receptor 
Teff   T effector cell 
TGF   transforming growth factor 
Th   T helper cell 
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1 General introduction 
 
Chapter 1 : General introduction 
1.1. B cells as target for new immunomodulatory drugs 
B cells play a considerable, but not yet fully understood, role as a pathogenic factor in 
different clinical situations such as cancer, (auto-) immune disorders, transplant rejection and 
graft-versus-host disease. Hence, the B cell represents a promising target for new drugs. As 
there is a strong unmet need to target B lymphocytes by specific drugs, there is a similar need 
for a broad in vitro immunoassay that could simplify the screening of such agents. Although 
in vitro assays have limitations, they form an approximation of the actual in vivo conditions 
and are essential to obtain insight into complex biological phenomena leading to new 
discoveries and predictions. 
1.2. B cell biology 
1.2.1. Development of B cells 
B cells are produced continuously throughout life and their development and differentiation 
occurs in multiple phases (Figure 1.1) requiring the coordinated action of a network of 
cytokines and transcription factors to form the various B cell subset phenotypes
1–5
 (Table 1.1). 
Two key processes characterize B cell maturation: 1) the generation of functional antigen-
specific receptors and 2) the selection of B cells that express useful antigen receptors. B cells 
initially arise from the foetal liver and then from hematopoietic stem cells that originate from 
the bone marrow and differentiate further into multi-potent progenitor cells, then into 
common lymphoid progenitor cells. Hereby, several transcription factors, EA2, EBF and 
Pax5, are crucial in promoting B cell lineage commitment and differentiation. Developing B 
cells then progress through rearrangement of immunoglobulin (Ig) heavy and light chain gene 
segments (variable V, diversity D, joining J), expression of cluster of differentiation (CD) 19 
and expression of recombination-activating genes RAG-1 and RAG-2 from pro-B to pre-B 
(with formation and surface expression of the pre-B cell receptor (pre-BCR) which delivers 
survival and further differentiation signals) to immature B cells, culminating in the expression 
of IgM mature B cell receptor (BCR) on the cell surface that can bind antigens. VH, DH and JH 
rearrangements of the heavy chain (H-chain) together with the VL-JL rearrangements of the 
light chain (L-chain) gene segments produce clonally-unique, Ig variable regions that 
specifically bind antigen. These maturation steps depend on close interactions between 
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developing B cells and bone marrow stromal cells, which provide critical adhesive integrins, 
growth factors, chemokines and cytokines. Immature B cells that display strong reactivity to 
self-antigen are subjected to negative selection through deletion, receptor editing or anergy. 
 
 
Figure 1.1. Schematic representation of B cell development. 
(Pre-)BCR, (Pre-)B cell receptor; BCR, B cell receptor; Breg, regulatory B cell; CSR, class switch 
recombination; GC, germinal centre; HSC, hematopoietic stem cell; Ig, immunoglobulin; PC, plasma cell; SHM, 
somatic hypermutation; T1 / T2 / T3, transitional 1 / 2 / 3 B cell. 
 
Immature B cells leave the bone marrow and home to secondary lymphoid tissues, 
preferentially to the spleen, to complete their maturation. Transitional B cells mark the crucial 
link between bone marrow immature and peripheral mature B cells and can be divided into 
T1, T2 and T3 B cells, according to surface phenotype, functional criteria and localization 
within the spleen. When transitional B cells in the spleen display a strong self-reactivity, they 
will be eliminated by clonal deletion. B cells can be separated into two lineages, B-1 and B-
2
2–4
, and each lineage plays distinct yet overlapping roles in humoral immunity. B-1 cells can 
be further sub-divided into B-1a (CD5
+
) that provide innate protection against bacterial 
infections (including via production of natural antibodies) and B-1b (CD5
-
) cells which 
respond to antigenic polysaccharides and other T cell-independent antigens. B-2 cells mature 
HSC
Pro
Pre
Im-
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Bone marrow
Generation of B cells
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Activation of B cells by foreign antigen
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further into marginal zone B cells (which are retained in the spleen) or follicular B cells 
(which recirculate in blood and secondary lymphoid tissues and are the major contributors to 
T cell-dependent immune responses) guided by BCR signals, B cell-activating factor 
(BAFF)
3,4
, a proliferation-inducing agent (APRIL)
3,4
 and expression of transcription factors, 
NOTCH2 (Notch family members play a role in a variety of developmental processes by 
controlling cell fate decisions) and Bruton tyrosine kinase (BTK)
5
. Mature B cells within the 
germinal centres of secondary lymphoid tissues come in contact with foreign antigens and 
with the help of T follicular helper cells they become triggered to proliferate, to differentiate 
and to undergo somatic hypermutation
3,5
 (a programmed process of mutation affecting the 
variable regions of Ig genes giving rise to clonal variants with altered antigen affinity and 
specificity) and class switch recombination
3
 (a recombination process in which one heavy 
chain constant region gene is replaced with another from a different isotype). During the 
germinal centre reaction, mature B cells give rise to memory B cells, regulatory B cells 
(Bregs), plasmablasts or plasma cells (PCs). 
Subsets Phenotype 
 Pro-B cell CD10+ CD19+ CD20- CD34+ RAG-1/2+ IgM-  
 Pre-B cell CD10+ CD19+ CD20+ CD34- RAG-1/2+ IgM- Pre-BCR 
 Immature CD10+ CD19+ CD20+ CD27- CD34- IgM+ 
 Transitional CD10+ CD19+ CD20+ CD24high CD27- CD38high IgMhigh BAFF-R+ 
T1
6
 CD21
low
 IgD
low
 
T2
6
 CD21
high
 IgD
high
 
T3
6
 CD10
low
 CD24
+
 CD38
+
 IgM
+
 IgD
+
 
 Naive mature CD19+ CD20+ CD27- CD38+ IgM+ IgD+ BAFF-R+ TACI+ 
 Marginal zone CD19+ CD20+ CD21high IgM+ IgDlow 
 Follicular CD19+ CD20+ CD21-/+ IgMlow IgD+ 
 Germinal centre CD19+ CD20+ CD38high IgM/G/A/E+ IgDlow BAFF-R+  
Bcl-6
+ 
 Plasmablast CD19+ CD20+ CD27high CD38high IgM/G/A/E+ IgD- 
Blimp-1
+ 
IRF4
high
 XBP1
+ 
 Plasma cell CD19low CD20- CD38high CD138+ IgM/G/A/E+ IgD- TACI+ and/or BCMA+ 
Blimp-1
high 
IRF4
high
 XBP1
+ 
 Memory B cell CD19+ CD20+ CD27+ CD38- IgM/G/A/E+ IgD- 
 Regulatory B cell7 CD1d+ CD5+ CD19+ CD20+ CD24high CD27- or + CD38high 
IL10
+
 BANK1
+
 GzmB
+
 Blimp-1
-
 PRDM1
- 
IRF4
-
 XBP1
-
 
Table 1.1. Overview human B cell subset phenotypes
3,4
. 
 
Cytokine IL21, which is produced mainly by T follicular helper cells, is found to be an 
important regulator for the generation of T follicular helper cells, germinal centre B cells and 
PCs through its capacity to moderate the expression of transcription factors B lymphocyte 
induced maturation protein 1 (Blimp-1) and B cell lymphoma-6 (Bcl-6)
8,9
. Memory B cells 
and PCs produce high-affinity, antigen-specific Igs, also termed antibodies (Abs) and form 
the basis of long-lived humoral immunity. Bregs from their part exert regulatory functions on 
innate and adaptive immunity to prevent that harmful excessive immune responses occur. 
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1.2.2. B cell actions and functional subsets 
The generation of Abs is the principal function of terminally differentiated B cells, such as 
plasmablasts and PCs. Abs are glycoproteins belonging to the Ig superfamily and constitute, 
through their specificity for a single antigenic determinant, the basis of the humoral immune 
response by clearing pathogenic invaders and their toxic products through several 
mechanisms of action like complement activation, direct anti-microbial functions, Ab-
dependent cellular toxicity and opsonisation
10
. The Y-shaped structure of the Ab typically 
consists of two identical large heavy chains and two identical small light chains, linked by 
disulphide bridges. The antigen-binding (Fab) fragment is composed of one constant and one 
variable domain of each of the heavy and the light chain. Antigen-binding sites are formed at 
the aminoterminal end of the variable domains of both the heavy and light chains and each 
arm of the Y structure binds an epitope on the antigen. The Fc region (the crystallisable 
fragment of the heavy chains) is the tail region that mediates interaction with effector 
molecules, such as complement and Fc receptors. In placental mammals, five isotypes or 
classes of Abs are known: IgA, IgD, IgE, IgG and IgM, as determined by the heavy chains, 
and they differ in their biological properties, functional locations and ability to deal with 
different antigens
11
. Plasmablasts are short-lived, proliferating effector cells of the early 
antibody response and their antibodies tend to have a weaker affinity towards their antigen 
compared to PCs. Unlike PCs, plasmablasts maintain CD20 expression
3,12
. PCs are long-
lived, non-dividing effector cells capable of producing large amounts of high-affinity, isotype-
switched Abs. Increased expression of Blimp-1 promotes the terminal differentiation of B 
lymphocytes into PCs
12
. Memory B cells are long-lived, quiescent B cells that recirculate 
through the body and can rapidly differentiate into Ab-secreting cells following re-exposure 
to antigen that had activated their parent B cell
3,5
. These cells contribute to humoral 
immunological memory that assures elimination of pathogens before the onset of clinical 
disease. 
B cells also have the ability to serve as efficient antigen-presenting cells (APCs), which are 
highly specialized cells that can process antigens and display their peptide fragments on the 
cell surface together with co-stimulatory proteins required for activating naive T cells. While 
other APCs like macrophages and dendritic cells internalize antigen through pinocytosis, B 
cells capture antigens through their antigen-specific BCR. Even at very low concentrations, 
antigens can be successfully presented in this manner
13
. The antigen-binding portion of the 
BCR complex is a cell-surface Ig that has the same antigen specificity as the secreted Igs that 
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the B cell will eventually produce. Engagement of antigen and BCR induces receptor 
oligomerisation and downstream signalling which promotes dynamic actin cytoskeletal 
rearrangements enabling efficient BCR-antigen internalisation into late endosomal 
compartments where the foreign proteins are degraded into peptide fragments, termed 
epitopes, which can bind to major histocompatibility complex (MHC) molecules for 
recognition by the appropriate T cells. MHC antigens, in the human also called human 
leukocyte antigen (HLA), are divided into two subgroups: Class I and Class II. MHC Class I 
(MHC I) are expressed on all nucleated cells and present epitopes to cytotoxic CD8
+
 T cells 
which then trigger the cell to undergo apoptosis. MHC Class II (MHC II) is normally 
expressed only on APCs and presents epitopes to the CD4
+
 T helper cells (Th cells). 
Successful interaction primes naive Th cells, which subsequently differentiate into other 
subsets such as memory T cells, effector Th cells (Th1 or Th2), regulatory T cells (Tregs), etc. 
In a transplant procedure, MHC molecules expressed on the graft act themselves as antigens 
and can provoke immune response in the recipient causing transplant rejection. Thus MHC 
antigens strongly determine compatibility of donors for organ transplantation. 
Cytokines are a large category of small proteins that play an important role in the 
communication between cells of multi-cellular organisms. As intercellular mediators, they 
regulate growth, survival, differentiation and effector functions of cells and initiate their 
action. They can act via an auto-, para-, or endocrine way and through specific cell-surface 
receptors on their target cells. B cells can actively regulate immune responses by producing 
distinct arrays of cytokines depending on the cellular subset they belong and on their mode of 
activation. B cell-derived cytokines include
14,15
: 1) Pro-inflammatory molecules, e.g. 
interleukin (IL) 1, IL2, IL4, IL6, IL8, interferon (IFN) γ, tumor-necrosis factor (TNF) α, 
lymphotoxin α (LTα); 2) Haematopoietic growth factors which are involved in the 
proliferation, differentiation, and survival of granulocytes, monocytes, macrophages, and 
bone marrow progenitor cells, e.g. granulocyte colony-stimulating factor, granulocyte-
macrophage colony-stimulating factor, macrophage colony-stimulating factor; and 3) Anti-
inflammatory molecules, e.g. IL10, IL35 and transforming growth factor (TGF) β. The 
cytokine profile of B cells is influenced by the cytokine microenvironment, T cell help 
through CD40 signalling, and through pathogen-derived toll-like receptor (TLR) ligands
16,17
. 
B cells primed by Th1 cells and antigen develop into the B cell effector 1 (Be1) subset, while 
B cells primed by Th2 cells and antigen develop into the B cell effector 2 (Be2) subset. These 
Be1 and Be2 subsets produce a substantially different cytokine signature, e.g. IL4 is produced 
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by the Be2 subset, but not by the Be1 subset. Conversely, IFNγ is produced by Be1 cells, but 
only at very minimal amounts by Be2 cells
18
.  
Bregs are immunosuppressive cells that support immunological tolerance and are critical to 
dampen inflammatory responses to infections. To restrain pro-inflammatory responses, Bregs 
suppress the differentiation of pro-inflammatory effector cells (such as Th1 cells, cytotoxic 
CD8
+
 T cells, Th17 cells, TNFα-producing monocytes and IL12-producing dendritic cells) 
and induce the differentiation of immunosuppressive Tregs. This is achieved through cognate 
interactions, mediated by MHC II and CD80/86, between Bregs and T cells and through the 
production of immunoregulatory cytokines IL10, IL35 and TGF β19. IL10 is considered the 
hallmark cytokine of many Breg subpopulations. Quite recently, IL35, a heterodimeric 
cytokine of the IL12 family, is documented as a novel suppressor molecule that is produced 
by a subset of Bregs distinctive from the IL10-expressing Bregs
20
. Observations in 
experimental models of autoimmunity (e.g. EAE
20
) and in mice with bacterial infection (such 
as Salmonella
20
) validate the hypothesis that IL10 and IL35 provide two largely separate 
suppressive pathways
21,22
. Different immunoregulatory B cell subsets have been described in 
mice and human subjects with distinct phenotypic properties. So far, no study has 
conclusively identified a Breg-specific transcription factor, similar to FoxP3 in Tregs. 
Remarkably, Bregs are found among B lymphocytes at different stages of maturation and 
differentiation, including early transitional B cells as well as highly differentiated 
plasmablasts and PCs. The inability to identify a unique transcription factor together with the 
heterogeneity of the phenotype of Bregs, support the idea that Bregs are not a separate lineage 
of B cells devoted to immunosuppression, but that they arise at various stages of B cell 
development in response to environmental, inflammatory stimuli
19,23,24
. B cells displaying a 
peculiar inhibitory profile have been described in the very rare cases of patients that show 
operational tolerance toward their kidney transplant (See paragraph 1.4.2.). The level of B 
cell-mediated suppression is controlled via a stepwise process initiated by intrinsic TLR 
signalling and then reinforced by signals via BCR and CD40. It sets the possibility for a 
negative feed-forward loop, which can allow an accelerated induction of immune responses 
while preventing excessive inflammation
17,25
. 
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1.2.3. Activation and regulation of B cells 
1.2.3.1. BCR signalling pathways 
Engagement of an antigen with the BCR on the outer surface triggers within the B cell a 
complex network of regulatory signalling cascades composed of kinases and phosphatases 
(Figure 1.2). The outcome of the response, which can be survival, apoptosis, anergy, 
proliferation, and differentiation into Ab-producing cells, memory B cells or Bregs, is 
depending on the duration and magnitude of the BCR signalling, the maturation state of the B 
cell, the nature of the antigen (T cell-dependent and T cell-independent B cell activation), and 
the accessory signals from co-stimulatory molecules, cytokine receptors, cytoskeleton, and B 
cell-activating factor-receptor (BAFF-R). The BCR is composed of a membrane Ig molecule 
and associated Igα/Igβ (CD79a/CD79b) heterodimers26. Each of the Igα and Igβ subunits 
contain a single immunoreceptor tyrosine-based activation motif (ITAM), which is composed 
of two conserved tyrosine (Tyr) residues. Antigen-induced BCR aggregation and 
conformational changes lead to Lck/Yes novel Tyr kinase (LYN)-mediated phosphorylation 
of ITAMs followed by the creation of docking sites for the recruitment of B lymphoid 
tyrosine kinase (BLK), proto-oncogene Tyr-protein kinases FYN, LYN, spleen Tyr kinase 
(SYK) and BTK. SYK and BTK are crucial components to couple BCR to more distal 
signalling
27,28
. SYK phosphorylates and activates the adaptor molecule B cell linker protein 
(BLNK) which binds to BTK and phospholipase Cγ2 (PLCγ2) resulting in an optimal 
phosphorylation and activation of PLCγ2 to promote the generation of diacylglycerol (DAG) 
and the influx of calcium (Ca
2+
) ions
26,29
. DAG and the Ca
2+
 ions activate in turn protein 
kinase Cβ (PKCβ), leading to activation of the RAS-RAF-MEK-ERK (also termed 
MAPK/ERK) pathway, and the CARMA1-, BCL-10- and MALT1-containing (CBM) 
complex, resulting eventually in the nuclear translocation of the p50-p65 NF-κB heterodimer. 
The cell surface molecule CD19 can amplify the BCR signal via activation of LYN and 
activation of phosphatidyl-inositol 3-kinase (PI3K). Activated PI3K phosphorylates the 
phospholipid phosphatidylinositol biphosphate (PIP2) resulting in the second messenger 
phosphatidylinositol triphosphate (PIP3). Phospholipids are a class of lipids and are a major 
component of all cell membranes. AKT, also called protein kinase B (PKB), is a 
serine/threonine (Ser/Thr) kinase that possesses a pleckstrin homology (PH) domain with high 
affinity for PIP3. AKT moves to the plasma membrane, binds PIP3, becomes activated by 
phosphoinositide-dependent kinase (PDK) 1 and PDK2-mediated phosphorylation (on Thr-
308 and on Ser-473 respectively) and regulates the cell growth, cell survival, cell migration 
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and cell metabolism and also the NF-κB signalling. Due to its critical role in regulating 
diverse cellular functions, AKT is an important therapeutic target for the treatment of human 
cancers. BCR activation affects also other signalling pathways such as Janus kinases (JAKs) 
and mammalian target of rapamycin (mTOR)
26–29
. The magnitude and duration of BCR 
signalling are limited by negative feedback loops including those involving the 
Lyn/CD22/SHP-1 pathway, the Cbp/Csk pathway, SHIP, Cbl, Dok-1, Dok-3, the low-affinity 
inhibitory IgG Fc receptor CD32b (also named FcγRIIB), PIR-B, and internalization of the 
BCR. Given the central role of BCR signalling in B cell malignancies and autoimmune 
diseases (AIDs), therapeutic approaches to inhibit BCR signalling are targeting crucial 
signalling nodes. 
 
 
Figure 1.2. A schematic representation of BCR signalling. 
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the latter. These bi-directional interactions are crucial for the development of an effective 
immune response. The immune system provides a plethora of diverse co-stimulatory 
molecules and they all contribute to the quality of the immune response. The function of a 
particular co-stimulatory molecule, which can either be stimulatory or inhibitory, is strongly 
related to the timing of its action. The expression of each co-stimulatory molecule and/or its 
ligand is tightly regulated and dependent on the activation status of the cell
30,31
. 
Numerous co-stimulatory molecules have been identified playing a role in the initiation of 
immune responses by T and B cells and the number is still increasing. Some relevant co-
stimulatory pathways with a crucial role in the B cell activation are briefly discussed below. 
The molecules involved in co-stimulation can roughly be classified as members from the TNF 
superfamily or from the Ig superfamily. 
1.2.3.2.1. TNF superfamily 
1.2.3.2.1.1. CD40 : CD40L pathway 
Binding of CD40 on APCs (B cell, dendritic cell, macrophage) with its ligand CD40L, also 
termed CD154, on T cells acts in a bi-directional fashion, mediating both humoral and cellular 
immune responses. B cells depend on CD40 for survival, expression of co-stimulatory 
molecules like CD80 and CD86 to interact with T cells, germinal centre formation, memory 
generation, Ig class switching and production of numerous cytokines and chemokines
32–35
. 
CD40 signals act via adaptor proteins known as TNF-receptor (TNFR)-associated factors 
(TRAFs) which mediate the activation of multiple signalling pathways that regulate 
transcription factors. CD40 has been reported to activate the canonical and non-canonical NF-
κB pathway as well as the extracellular signal-regulated kinase (ERK), c-Jun N-terminal 
kinase (JNK), p38 mitogen-activated protein (MAP) kinases, and PI3K pathways. These 
pathways involve Ser/Thr kinases or Tyr kinases that regulate gene expression through 
phosphorylation and activation of transcription factors. Mutations in either the CD40 or 
CD40L gene cause the hyper IgM syndrome, termed HIGM3 or HIGM1 respectively, 
characterized by very low levels of serum IgG, IgA, and IgE, but normal or elevated IgM, 
associated with defective Ig class switching and germinal centre formation
36–38
. Aberrant 
expression of CD40 has been associated with various cancerous malignancies
34
 and with 
AIDs such as multiple sclerosis (MS)
39
. CD40L is over-expressed on T and B cells in 
systemic lupus erythematosus (SLE)
40
. Blocking of CD40L, for instance by antagonistic 
CD40L mAbs (clone MR1), contributes to prolonged graft survival and seems to be 
synergistic when combined with immunosuppressive drugs (e.g. rapamycin) and other co-
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stimulatory blockade(s)
34
. Despite promising results in non-human primates, CD40L 
antibodies have not yet reached clinical application because of the possible risk of 
thrombosis
41
. The latter may, however, change soon as non-thrombotic anti-CD40L Abs are 
in the stage of development (e.g. CDP7657
42
). 
1.2.3.2.1.2. CD70 : CD27 pathway 
The precise functional role of the CD70 : CD27 pathway in B cells remains only partially 
understood, but data from human MS, rheumatoid arthritis (RA) or SLE patients
43
 and murine 
disease models of MS, RA, SLE and inflammatory bowel disease
43
 document a significant 
role for the CD70 : CD27 surface ligand-receptor pair in providing co-stimulatory signals that 
regulate T cell and B cell activation and differentiation. CD27 belongs to the TNF-R family 
and is found on the majority of T cells, on subsets of natural killer cells, and hematopoietic 
stem cells. CD27 is not expressed by naive B cells, but is up-regulated in activated and 
antigen-experienced B cells. After the initial up-regulation CD27 can persist at high levels, 
making it a typical marker for memory B cells
43–45
. CD70-induced triggering of CD27 on T 
cells contributes to the formation of the effector T cell pool by efficient priming of T cells and 
the subsequent promotion of T cell survival via the canonical and non-canonical NF-κB 
pathways as well as the JNK pathway via TRAF2 and TRAF5 adaptor proteins
30,45,46
. CD70, 
characterized as the unique natural ligand of CD27, is transiently expressed on the surface of 
activated B cells, T cells and dendritic cells. Studies with transgenic CD27
-/-
 x CD70 Tg mice 
that constitutively express CD70 on all B lymphocytes, but concomitantly lack CD27, 
indicate that CD70 engagement on B cells couples to both PI3K and MEK pathways, resulting 
in phosphorylation of their downstream targets AKT and ERK1/2
43
 (Figure 1.3). Further, 
there is not much known about the signalling downstream of CD70. 
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Figure 1.3. Signalling pathways mediated by CD70-CD27 interactions. 
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lymphocytic leukemia, and large B cell lymphomas, and on various other malignancies, 
implying that CD70 is an attractive candidate for cancer immunotherapy
30,43,44,46,51
. 
1.2.3.2.1.3. BAFF and APRIL signalling 
Together with their cognate receptors, BAFF and APRIL regulate B lymphocyte homeostasis. 
Both ligands belong to the TNF superfamily and are predominantly produced by 
macrophages, neutrophils, and dendritic cells, but can also be produced by lymphoid cells, 
including B cells and activated T cells
52
. BAFF, also known as B lymphocyte survival factor 
(BLyS), plays a significant role in promoting B cell survival, maturation, proliferation and 
differentiation
52
. BAFF is expressed as a membrane-bound trimer, which is proteolytically 
cleaved to form a soluble trimer and binds with three different receptors expressed on B cells 
at different stages of maturation: BAFF-receptor (BAFF-R), B cell maturation antigen 
(BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand 
interactor (TACI). The predominant receptor on human peripheral B cells is BAFF-R, while 
BCMA and TACI appear to be preferentially expressed on PCs and transitional B cells, 
respectively
53
. APRIL, which acts as a co-stimulator for B and T cell proliferation and 
supports class switching, is recognized by both BCMA and TACI
54
. Deregulation of the 
BAFF/APRIL system can lead to malignancies of B cells and PCs
55
 and to AIDs such as SLE 
and Sjögren‟s syndrome. SLE and Sjögren‟s syndrome patients have high levels of BAFF 
which may contribute to altered differentiation of B cells
56
. An improvement of symptoms in 
patients with SLE can be obtained by treatment with belimumab, an anti-BAFF monoclonal 
antibody
57
. 
1.2.3.2.2. Co-stimulatory Ig superfamily 
1.2.3.2.2.1. CD80/CD86 : CD28 pathway 
CD80 and CD86, also named B7.1 and B7.2 respectively, are two structurally related proteins 
that can be found on the cell-surface of APCs, such as dendritic cells, B cells and 
macrophages, and are the major co-stimulatory molecules for CD4
+
 Th cells. Both CD80 and 
CD86 are capable of binding the stimulatory CD28 on Th2 cells, hereby delivering to the Th2 
cell the necessary second signal for its survival and activation. Upon activation, the Th2 cell 
up-regulates the expression of CD40L. In turn, T cell delivers the co-stimulatory signal for 
activation to the B cell via ligation of CD40L with CD40 on the B cell. While CD28 
expression on T cells is constitutive, the expression patterns of the CD80 and CD86 molecules 
are variable
58,59
. In general, CD86 seems to be constitutively expressed at low levels and can 
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be rapidly up-regulated. Expression of CD80 can be induced on activated B cells, 
macrophages and natural killer cells, but the time course of induction of expression is slower 
than that of CD86
60
. In spite of the high degree of homology and the substantially overlapping 
functions, there are indications for distinct effects of CD80 and CD86 on T (regulatory
59
) cell 
responses
60
 and on B cell activation and differentiation
61
. In studies with lipopolysaccharide 
(LPS)-stimulated murine B cells, it was shown that triggering through CD80 specifically 
inhibited the proliferation and IgG secretion while, by contrast, triggering through CD86 
augmented the B cell activity. Also it was determined that CD86 had a higher relative affinity 
for activating CD28, while CD80 seemed to have a higher relative affinity for inhibitory 
cytotoxic T lymphocyte- associated antigen 4 (CTLA4)
61
. Hence, CD80 and CD86 may 
mediate differential signal transduction which could distinctly regulate the B cell‟s effector 
function. There is not much known about the signalling downstream of CD80 and CD86, but 
murine as well as human CD80/CD86 cytoplasmic tails contain potential binding motifs for 
different kinases
61,62
, suggesting that different signalling can be initiated upon activation. 
Abatacept and belatacept are inhibitors for CD80/CD86-mediated co-stimulatory signalling 
(See further „CD80/CD86 : CTLA4 pathway‟). 
1.2.3.2.3. Co-inhibitory Ig superfamily 
1.2.3.2.3.1. CD80/CD86 : CTLA4 pathway 
Upon activation, T cell up-regulate the negative co-stimulatory molecule CTLA4, also known 
as CD152. This molecule binds the same ligands as the activating CD28, namely CD80 and 
CD86, but with a 20-100 fold higher affinity. CTLA4 functions as an inhibitory receptor 
important for down-modulating the immune response through a negative feedback loop
58,63
. 
Ligation of CD80 and CD86 with CTLA4 also transmits outside-in signals to the APC 
resulting in a down-modulation in expression of CD80 and CD86
64
. Fusion protein CTLA4-Ig 
prevents CD28 signals by outcompeting CD28 for binding to its ligands CD80/CD86. 
Abatacept is such a CTLA4-Ig composed of the Fc region of the IgG1 fused to the extra-
cellular domain of CTLA4 and is used in the treatment of RA. Through its binding to the 
CD80 and CD86 molecule, abatacept prevents the co-stimulatory signal necessary for T cell 
activation
65
. Second-generation CTLA4-Ig, belatacept, shows increased binding affinity 
compared to abatacept and is intended to ameliorate graft survival in transplantation while 
limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin 
inhibitors cyclosporine A and tacrolimus
66,67
. 
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1.2.3.2.3.2. CD83 
The molecule CD83 was long considered as a specific maturation marker for dendritic cells, 
but is gaining more interest in studies on B cells and T cells. It belongs to the Ig superfamily 
and is strongly expressed on activated murine and human dendritic cells and on many immune 
cells upon activation, including B cells and T cells. CD83 is rapidly up-regulated on murine B 
cells after either TLR engagement by LPS or after BCR ligation
68–70
. Transgenic over-
expression of CD83 on B cells in mice interferes with T cell-dependent and T cell-
independent Ig production during infection in vivo
71
. Furthermore, the forced over-expression 
of CD83 on B cells results in increased MHC II and CD86 expression, reduced proliferation, 
reduced Ca
2+
 signalling, lowered Ig secretion and increased IL10 production upon in vitro 
activation by LPS
70
. Diminished CD83 expression in CD83-mutant mice gives a reduction in 
IL10 release and a slight increase in Ig secretion which are not correlated to impaired B cell 
function
70
. So CD83 might act as a negative regulator and is assumed to be involved in the 
down-modulation of B cell responses. Thereby CD83 interferes with early BCR-mediated 
signalling events such as phosphorylation of LYN and SYK, consequently leading to reduced 
activation of distal effectors such as ERK1/2
72
 and Ca
2+
 influx
70
. How CD83 mediates its 
inhibitory effects and the nature of the putative CD83 ligand are not yet known, but are 
currently under investigation. 
1.2.3.2.3.3. PD-L1/2 : PD-1 pathway 
Programmed cell death (PD)-1 shares homology with CTLA4 and CD28 and is expressed on 
activated CD4
+
 and CD8
+
 T cells as well as on activated B cells, natural killer cells and 
macrophages. Programmed cell death-ligand 1 (PD-L1, B7-H1) and programmed cell death-
ligand 2 (PD-L2, B7-DC) interact with PD-1
73
. PD-L1 is constitutively expressed on T cells, 
B cells, myeloid cells and dendritic cells and can be up-regulated upon activation. In addition, 
PD-L1 is also expressed by non-hematopoietic cells (e.g. microvascular endothelial cells), 
non-lymphoid organs (e.g. heart, lung, muscle and placenta), and a variety of tumours. PD-
L2, however, is restricted to macrophages, mast cells and dendritic cells. The presence of 
immunoreceptor Tyr-based inhibition motif (ITIM) in the intracellular domain of PD-1 and 
the observation of an autoimmune phenotype with SLE-like glomerulonephritis and 
progressive arthritis in PD-1 KO mice
74
 postulated a role for the PD-1 pathway in negatively 
regulating immune responses. However, the regulation of alloimmunity by the PD-1/PD-L1/2 
pathway proved to be complex due to the differences in tissue distribution of the ligands for 
PD-1, suggesting that PD-L1 and PD-L2 may exert different functions in immune regulation, 
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and the presence or absence of CD28 co-stimulation seems to have a considerable impact on 
the functionality of the PD-1 pathway
73,75,76
. 
1.2.3.3. Toll-like receptors 
Throughout vertebrate evolution, TLRs have remained highly conserved, and represent a 
critical link between the innate and the adaptive immunity. As sentinels of the host innate 
immune system, they recognize specific molecular patterns on invading microorganisms, so-
called pathogen-associated-molecular-patterns (PAMPs), and damage-associated molecular 
pattern molecules that are released by stressed cells undergoing necrosis. In humans, ten 
TLRs have been characterized. TLRs 1, 2, 4, 5, 6 and 10 are expressed at the cell membranes 
and recognize bacterial, fungal and parasite-derived ligands. TLRs 3, 7, 8 and 9 are expressed 
in the endosomes and recognize viral and bacterial RNA and DNA
77
. Except for TLR3, the 
TLRs (TLR7/8/9 signalling is represented in figure 1.4) are coupled to the adaptor protein 
myeloid differentiation primary response gene-88 (MyD88) which starts a signalling cascade 
through MyD88/IL-1 receptor-associated kinase (IRAK) 1/IRAK4/ TRAF complexes ending 
up in the activation of MAP kinases (JNK, p38 MAPK) and of transcription factors NF-κB, 
interferon regulatory factors (IRFs), cAMP response element-binding protein (CREB) and 
activator protein 1 (AP-1), leading to the induction of several inflammatory genes. TLRs are 
expressed by immune cells like macrophages, dendritic cells, polymorphonuclear cells, and 
mast cells as well as T and B cells of the adaptive immune system, and by epithelial, 
endothelial and mesenchymal cells of various organs and tissues. These cells all have 
characteristic TLR expression patterns which can direct their specific behaviour
77
. 
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Figure 1.4. A schematic representation of TLR7/8/9 signalling. 
 
In contrast to naive murine B cells, human B cells seem to lack significant expression of 
TLR4, the receptor for LPS
78,79
. Human B lymphocytes mainly express endosomal TLR7 and 
TLR9. Human TLR7 is often grouped together with TLR8 for sharing a similar structure, 
genomic localization and common ability to detect single-stranded RNA (ssRNA), although 
TLR8 has a function on its own in the initiation of specific pro-inflammatory responses to 
viruses and bacteria and is predominantly expressed on monocytes
80
. Human TLR9, which is 
constitutively expressed in the endosomes of B cells and plasmacytoid dendritic cells, is 
essential for responses to bacterial and viral CpG-containing DNA
81,82
. The level of TLR9 
expression is dependent on the state of B cell maturity and activation
83–85
. 
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TLRs have been implicated to play a significant role in various major diseases, including B 
cell malignancies and B cell-related AIDs. Recent studies have revealed that TLR9 is 
overexpressed in peripheral blood B cells isolated from patients with active SLE
86,87
. 
In transplantation, TLRs can facilitate allograft rejection. During the operation, surgical stress 
and ischemia reperfusion injury can provoke the release of endogenous (e.g. derived from 
apoptotic or necrotic cells, heat shock proteins and degradation products of extracellular 
proteins) and exogenous (e.g. commensal bacteria in skin, small bowel and lung) ligands that 
can activate TLRs which in turn initiate innate immunity and adaptive immune responses
77
. 
Although in vivo evidence for TLR-mediated suppression in transplantation is scarce, TLR 
signalling may also enhance regulatory loops controlling early inflammatory events post-
transplantation and ultimately promote allograft acceptance
77,88
. 
At the moment, the use of TLR ligands as vaccine adjuvants forms a topic of great interest for 
clinical application in inflammatory and infectious diseases and cancer
87,89
. 
1.3. B cell-related pathologies and current treatment(s) 
1.3.1. Cancer 
Many different B cell malignancies have been described, e.g. non-Hodgkin‟s lymphoma, 
Hodgkin‟s lymphoma, Burkitt‟s lymphoma, diffuse large B cell lymphoma and follicular 
lymphomas
26
. B cell lymphomas are divided into low and high grade, typically corresponding 
to indolent, slow-growing lymphomas and aggressive lymphomas, respectively. Generally, 
the aggressive lymphomas are curable, but require intensive treatments. Indolent lymphomas 
respond to treatment and are kept under control (in remission) with long-term survival. 
Treatment, which includes radiation and chemotherapy, depends on the specific type of B cell 
malignancy as well as stage and grade. Inhibitors of PI3K (idelalisib
90
), SYK (fostamatinib
27
, 
entospletinib
91
), and BTK (ibrutinib
27
) have shown promising results in clinical trials for 
treatment of B cell neoplasms, such as B cell chronic lymphocytic leukaemia, B cell non-
Hodgkin‟s lymphoma and diffuse large B cell lymphoma26. 
1.3.2. Autoimmune diseases 
AIDs arise from an abnormal immune response of the body against substances and tissues 
normally present in the body and are after cancer and atherosclerosis the third major cause of 
morbidity and mortality
92
. In the United States, 23.5 million up to 50 million citizens suffer 
from an AID (the numbers continue to increase!) and it is estimated that 80 to 100 different 
forms of AIDs exist. AIDs have no clear cause for their development, they are difficult to 
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diagnose due to their slow evolution and they are chronic and life-long diseases for which a 
solid treatment method does not exist. The annual direct health care costs increase to more 
than US$ 100 billion (National Institutes of Health www.nih.gov and American Autoimmune 
Related Disease Association www.aarda.org). Treatment for AIDs typically consists of 
immunosuppressive medication that reduces the activation or efficacy of the immune system. 
Through their different functions, B cells can contribute to the development of AIDs: 
1) Secretion of autoAbs 
The presence of autoAbs in the peripheral circulation can be detected in many AIDs. 
Immune complexes composed of autoAbs and autoantigens can trigger inflammation 
through activation of the complement system and through binding with Fc-receptors 
inducing Ab-dependent-cell-mediated cytotoxicity. AutoAbs can also stimulate or 
inhibit the function of different kinds of receptors with ligands as hormones, 
neurotransmitters or peptides
93
. 
Natural autoAbs can have a protective function by, for instance, clearing dying and 
aging cells which may otherwise elicit a pathogenic autoimmune response. Another 
mechanism of protection is the blockage of pathogenic autoAbs to react with self-
antigen
93
. 
2) Presentation of autoantigens and T cell activation 
B cells function as very efficient APCs by capturing the autoantigen, even at very low 
concentrations, through their BCR and present it complexed with MHC to Th cells for 
activation. 
3) Secretion of pro-inflammatory cytokines 
Activated B cells can produce various pro-inflammatory cytokines, including IL2, IL4, 
IL6, IFNγ and TNFα, which can activate other effector immune cells and provide 
feedback stimulatory signals for further B cell activation. 
4) Formation of ectopic germinal centres 
During periods of chronic inflammation B cells aid in the formation of ectopic 
germinal centres within inflamed tissues. These structures are similar to the germinal 
centres in secondary lymphoid organs (e.g. spleen, lymph nodes, tonsil, Peyer‟s 
patches), however, their function and potential pathogenic role remains to be 
determined. It is plausible that ectopic germinal centres have a role in the maintenance 
of immune pathology, because the PCs residing within the ectopic germinal centres 
secrete autoAbs
93
. 
Three prominent AIDs are discussed below. 
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1.3.2.1. Rheumatoid arthritis 
RA is a disorder that primarily affects the joints of musculo-skeletal system causing 
significant pain and physical disability, but also serious co-morbidities such as increased risk 
of cardiovascular disease, serious infections, lung cancer, lymphoma and premature death. 
The list of RA-associated autoAbs continues to expand. The most widely studied autoAb 
systems are rheumatoid factors (autoAbs against Fc portion of IgG) and Abs against 
citrullinated peptides. But the contribution of B cells to RA pathogenesis goes beyond autoAb 
production. Antigen presentation, delivery of co-stimulatory signals and secretion of 
cytokines
94,95
, including IL1α, IL6, IL12, IL23 and TNFα, induce the activation and 
differentiation of effector T cells. The synovial membrane, a layer of connective tissue that 
lines the cavities of joints, tendon sheaths, and bursae, forms a preferential environment for 
the T cell and B cell interactions. Destructive inflammatory synovitis is the consequence of 
the infiltration of macrophages, T cells and B cells into the synovial membrane. B cells also 
participate in the activation of osteoclasts, bone cells that break down bone tissue, leading to 
destruction of bone and cartilage. Specific subsets of B cells can function as regulatory 
elements through the provision of IL10, the B10 cells. However, their suppressive function is 
partly impaired during active disease and their frequency in the systemic circulation is 
reduced compared to healthy individuals
94
. 
Therapy for RA consists generally of a combination of several medications. Disease 
modifying anti-rheumatic disease drugs (DMARDs) consist of anti-inflammatory agents that 
slow down the disease progression. Many different drugs with different mechanisms of action 
can be used as DMARDs in the treatment of RA, but some are used more often than others. The 
most prevalent: methotrexate, azathioprine and leflunomide are well-known anti-proliferative 
agents with inhibitory effects on DNA-synthesis; adalimumab (anti-TNF monoclonal Ab) and 
etanercept (fusion protein TNF inhibitor) neutralize pro-inflammatory TNFα; abatacept 
(CTLA4-Ig fusion protein) is a B cell - T cell co-stimulatory signal inhibitor; rituximab (anti-
CD20 monoclonal Ab) causes B cell depletion; tofacitinib (an inhibitor of JAK1 and JAK3) 
interferes the JAK - STAT signalling pathway; and (hydroxy-) chloroquine increases pH 
within intracellular vacuoles and alters processes such as protein degradation by acidic 
hydrolases in the lysosome, assembly of macromolecules in the endosomes, and post-
translation modification of proteins in the Golgi apparatus, resulting in a diminished 
formation of peptide-MHC protein complexes required to stimulate CD4
+
 T cells
96
. Non-
steroidal anti-inflammatory drugs (NSAIDs) and (cortico-) steroids are anti-inflammatory 
medicine used to relieve pain and reduce inflammation. 
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The collagen-induced arthritis mouse model is the most commonly studied autoimmune 
model of RA wherein autoimmune arthritis is induced through immunization with an 
emulsion of complete Freund's adjuvant and type II collagen
97
. 
1.3.2.2. Systemic lupus erythematosus 
SLE is a chronic multi-organ AID characterized by a complex multi-factorial pathogenesis 
and a great clinical polymorphism. B cells carry out central roles in the pathogenesis of SLE 
through a combination of Ab-dependent and -independent actions. A hallmark is the 
production of autoAbs (anti-dsDNA, anti-cardiolipin, anti-Ro Abs) and the deposition of 
immune complexes resulting in glomerulonephritis and proteinurea, congenital heart block 
and thrombosis
98
. The Ab-independent role is related to the T cell and B cell crosstalk, 
including the presentation of self-antigens and the delivery of co-stimulatory signals, and the 
elevated production of cytokines IL6, IL10 and IFNα. 
The most current treatment of SLE is directed toward easing the symptoms by decreasing 
inflammation and level of autoimmune activity with NSAIDs and (hydroxy-) chloroquine for 
those with mild symptoms and corticosteroids and immunosuppressive agents such as 
mycophenolate mofetil, cyclophosphamide, azathioprine, and methotrexate, for those with a 
more severe disease status. SLE patients show an excess of circulating BAFF leading to 
aberrancies in the B cell homeostasis. Treatment with belimumab, a fully human anti-BAFF 
monoclonal Ab, or with atacicept, a TACI-Ig fusion protein that neutralizes both BAFF and 
APRIL, is a manner to restore the B cell homeostasis
57
. In contrast to the success of B cell 
depletion with rituximab for the treatment of RA, randomized, placebo-controlled trials of 
rituximab failed to meet their primary or secondary clinical endpoints for renal and non-renal 
SLE
99,100
. IL10 serum levels are significantly elevated in human SLE and correlate with 
disease activity. Increased IL10 production accounts for the impairment of T lymphocyte 
function and the maintenance of B cell‟s hyperactivity and autoAb secretion. Secretion of 
autoAbs was significantly reduced in the presence of neutralizing IL10 specific monoclonal 
Abs and led to marked improvement in participants of a small clinical trial
101
. The importance 
of CD32b (FcγRIIB), the sole inhibitory member of the FcγR family with expression on B 
cells, plasmablasts and long-lived PCs and an important role in the down-regulation of Ab-
production
102
, is exemplified by the finding that B cells from SLE patients express lower 
levels of CD32b on their surface due to polymorphisms in their CD32b promoter
103
 or in the 
receptor itself
104,105
. Agonistic CD32b Abs could show therapeutic potential, but their efficacy 
could be compromised by the decreased expression of CD32b in SLE B cells and PCs
100
. 
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Epratuzumab, an anti-CD22 B cell modulator, holds great promise as novel therapeutic for 
patients suffering from moderate-to-severe SLE
106
. 
There are numerous murine (spontaneous and induced) models of SLE and all of them portray 
their own iterations of lupus-like diseases with a subset of symptoms akin to those observed in 
human SLE, namely, autoAb production, lymphoid activation and hyperplasia, and lupus 
nephritis. The classic models of spontaneous lupus include the F1 hybrid between the New 
Zealand Black and New Zealand White strains (NZB/W F1) and its derivatives, the MRL/lpr, 
and BXSB/Yaa strains whereas induced models include the pristane-induced model and the 
chronic graft-versus-host-disease models
107
. 
1.3.2.3. Multiple sclerosis 
MS is a progressive inflammatory and demyelinating disease of the human central nervous 
system in which the insulating myelin sheath of nerve cells in the brain and spinal cord are 
damaged. Nerve impulses travelling to and from the brain and spinal cord are distorted or 
interrupted, causing a wide variety of autonomic, visual, motor and sensory problems. 
The role of B cells in the pathogenesis of MS is diverse: autoantigen presentation (for instance 
myelin oligodendrocyte glycoprotein and myelin basic protein); secretion of autoAbs in 
cerebrospinal fluid; formation of ectopic lymphoid follicles. Generally, MS patients have 
normal numbers of circulating B cells and PCs, but show an increased number of B cells, 
mainly memory B cells and plasmablasts, in the central nervous system
108
. Plasmablasts 
persist in the cerebrospinal fluid throughout the course of MS and correlate with intrathecal 
IgG synthesis and with active inflammatory parenchymal disease. MS lesions, known as 
„plaques‟, may form in central nervous system‟s white matter in any location and contain B 
cells and PCs, but also both CD8
+
 and CD4
+
 T cells permitting interactions between B cells 
and T cells which result in the activation of T cells and their differentiation into Th1, Th2, or 
Th17 cells and in the T cell-dependent B cell activation with detrimental consequences
108
. 
Cytokines TNFα, IL1, IL2, IL4, IL6 and IL10 are identified within MS lesions and especially 
BAFF is found to be strongly elevated in the demyelinating MS lesions and might be involved 
in the formation of lymphoid follicle-like meningeal structures
108,109
. Increased APRIL 
expression in astrocytes has been noted in the brain of MS patients
110
. 
Several therapeutic substances are developed to abolish the migration of immune cells, 
generally T cells, across the blood-brain barrier toward the central nervous system: therapy 
with cytokine interferon-β1 leads to a reduction of neuron inflammation by decreasing the 
number of inflammatory cells (through inhibition of T cell activation and proliferation, 
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apoptosis of auto-reactive T cells, induction of Tregs) that cross the blood-brain barrier and by 
increasing the production of nerve growth factor
111
; humanized monoclonal Ab natalizumab 
binds to α4β1-integrin on leukocytes and blocks its interaction with VCAM-1 on endothelial 
cells; and pro-drug fingolimod works as a functional antagonist on the sfingosine 1-phosphate 
receptor type 1 on lymphocytes. Glatiramer acetate is a random polymer composed of 4 
amino acids found in myelin basic protein and shows an initial strong promiscuous binding to 
major histocompatibility complex molecules and consequent competition with various myelin 
antigens for their presentation to T cells. Anti-CD20 rituximab, ocrelizumab and ofatunumab, 
anti-CD52 alemtuzumab and anti-BAFF agents belimumab and tabalumab aim at a depletion 
of pathogenic effector B and T lymphocytes
108,109
. Treatment with recombinant fusion protein 
atacicept, designed to neutralize the high levels of BAFF and APRIL, gave unexpectedly 
increased disease activity
108
 and was withdrawn from clinical MS trials. Teriflunomide 
(dihydroorotate dehydrogenase inhibitor) and mitoxantrone (type II topoisomerase inhibitor) 
are anti-proliferative agents. Dimethyl fumarate, derived from the organic acid fumaric acid, 
holds great promise for modern immunotherapy in MS with a broad efficacy, good safety and 
satisfying tolerability, but its (main) mechanism of action has not yet been clarified. 
Experimental autoimmune encephalomyelitis is a CD4
+
 T cell-mediated AID characterized by 
perivascular CD4
+
 T cell and mononuclear cell inflammation and subsequent primary 
demyelination of axonal tracks in the central nervous system, leading to progressive hind-limb 
paralysis. It is generally considered to be a relevant animal model for MS
112
. 
1.4. Solid organ transplantation 
Organ transplantation is the treatment of choice when a patient has a defective or severely 
injured vital organ. Vital physiologic functions are restored through the surgical substitution 
of the defective organ of the patient, the recipient, by a healthy organ from a donor. However, 
solid organ transplantation is not risk-free. Serious short-term and long-term complications 
can occur, either related to the transplantation procedure itself or to the immunosuppressive 
drugs to prevent the rejection of the allograft. 
The significant development of immunosuppressive drug therapies has had a major impact on 
the outcome of clinical solid organ transplantation, mainly by decreasing the incidence of 
acute rejection episodes and improving short-term patient and graft survival. Amongst the 
immunosuppressive drugs there are corticosteroids like prednisolone and hydrocortisone, 
calcineurin inhibitors like cyclosporine A and tacrolimus, mTOR inhibitors like rapamycin, 
and anti-proliferatives like azathioprine and mycophenolic acid. Monoclonal Abs selective 
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against immune components can also be used in immunosuppressive therapy. Unfortunately, 
long-term results remain disappointing because of chronic allograft dysfunction and the 
necessary chronic use of immunosuppressive drugs leads to two categories of complications: 
(1) drug-related adverse effects such as hypertension, cardiovascular complications, renal 
dysfunction, hyperlipidemia and diabetes mellitus; and (2) higher susceptibility to bacterial, 
fungal and viral infections and increased risk of developing a wide range of cancers due to the 
reduced function of the naturally-occurring immune system in the body
113,114
. Hence, 
immunosuppressants, although they are necessary to take, can have a serious impact on the 
quality of life of the patient. Furthermore, the worldwide acute shortage of human donor 
grafts (USA: 30 973 transplants from 15 064 donors have been performed while more than 
121 000 candidates were on the waiting list in the year 2015
115
) makes the situation for people 
waiting for (another) transplant very problematic. It urges to find new strategies to optimize 
the current therapies and also to find other ways to meet the demand of organs (either by non-
human derived organs for xeno-transplantation or by bio-engineered grafts from stem cells). 
The current “one size fits it all” strategy will certainly be substituted, because 
immunosuppression needs to be managed according to the quality of the transplanted organ, 
patient co-morbidity profile, underlying graft inflammatory status, and degree of cellular 
and/or humoral sensitization
116
. 
The focus of B cell research in clinical transplant immunology has been mostly directed to 
neutralize or avoid the production of donor-specific Abs (DSAs) which play an important role 
in humoral rejection. However, the role of B cells in organ transplantation is not restricted to 
the production of Abs. Moreover, B cells can also act as beneficial players in the tolerance of 
the allograft
117
. 
1.4.1. Contribution of B cells to rejection of the allograft 
As a consequence of a sensitization event before transplantation (e.g. blood transfusion, 
previous transplantation or pregnancy), pre-formed circulating DSAs, directed against donor-
specific HLA, can be present in the recipient‟s immune system. These DSAs cause via 
complement-dependent or -independent pathways early morbidity and graft loss in early 
(hyper-) acute antibody-mediated rejection, mostly occurring a few days to weeks after 
transplantation. At later time points after transplantation, chronic antibody-mediated rejection, 
due to de novo Ab production, may occur alone or in combination with cellular reactions and 
results in irreversible structural damage
118
. The protocols used for pre-transplant 
desensitization and post-transplant treatment of (hyper-) acute antibody-mediated rejection are 
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based on elimination or reduction of circulating Abs, inhibition of residual Abs, and 
suppression or depletion of B cells
119
. Plasmapheresis and intravenous immunoglobulin 
(IVIG) are techniques to remove directly harmful alloAbs from the patient‟s plasma. The 
chimeric anti-CD20 Ab, rituximab, is a well-known B cell depleting agent, but its effect in the 
desensitization is limited. AlloAb titers remain generally unaltered, because PCs, which lack 
CD20, and memory B cells, which have only low expression of CD20, are not affected by 
rituximab. New strategies to deplete alloAb-producing B cells involve 26S proteasome 
inhibitor bortezomib and anti-CD52 Ab alemtuzumab. Bortezomib can strongly reduce 
circulating PC numbers through apoptosis induction
120,121
. Alemtuzumab provides a high 
spectrum depletion of circulating B cells as CD52 is expressed from the pro-B to the short-
lived PC stages. Eculizumab
122
, an anti-C5 Ab, diminishes complement-mediated 
pathogenesis. Splenectomy can be performed in highly sensitized patients in whom 
desensitization therapy has failed. 
B cells can act as APCs which deliver the required multiple signals for activation and 
differentiation of the recipient T cells. Recipient CD4
+
 T cells usually acquire helper function 
and can on their turn influence B cell activation, differentiation and Ab production by the 
production of cytokines
123–125
. At later stages of graft rejection B cells can infiltrate into the 
graft tissue and form ectopic germinal centres or so-called tertiary lymphoid tissue. These 
structures direct various B cell and T cell responses, including the induction of effector 
functions, Ab generation, affinity maturation, Ig class switching and clonal expansion
126
. In 
the end, all these actions, classified under the process of chronic rejection, lead to destruction 
and rejection of the donor graft. Chronic rejection is generally considered irreversible and 
poorly amenable to treatment. 
1.4.2. Contribution of B cells to tolerance of the allograft 
Emerging data from both experimental animal models
127–133
 and clinical trials indicate that 
Bregs can act as beneficial players in the protection and acceptance of the allograft. 
Operational tolerance is a very rare clinical situation in which the patient shows a stable graft 
function without clinical features of rejection in the absence of any immunosuppressive drugs 
for more than a year
134,135
. Extensive research was done on the characterization of the B cells 
of operationally tolerant kidney transplant patients. Apparently, as determined in a 
comparative study between healthy people and kidney-transplanted individuals with 
operational tolerance, individuals with stable graft function under immunosuppression and 
individuals with chronic rejection, the state of operational tolerance essentially involves the 
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preservation of a healthy B cell compartment profile and not a higher activation or expansion 
of B cells
136
. Phenotypically, peripheral blood B cells of tolerant patients display an inhibitory 
profile
137
, defined by an increased expression of BANK1 (a negative modulator of CD40-
mediated AKT activation)
138,139
, CD1d (usually characterizing for cells with regulatory 
phenotype; it presents lipid antigens to natural killer T cells)
140–142
 and CD5 (negatively 
regulates BCR signalling)
143
, as well as a decreased ratio of CD32a/CD32b
144–146
. 
Particularly, tolerant patients display a higher absolute number of GzmB-expressing B cells 
with a PC-like phenotype and suppressive properties. They can inhibit in vitro the 
proliferation of effector CD4
+
CD25
-
 T cells in a contact- and GzmB-dependent manner
147
.  
 
Healthy volunteer Tolerant kidney patient 
Stable graft under 
immunosuppression 
Chronic rejection under 
immunosuppression 
B cells (% and total number) Maintenance of B cells Decrease in B cells Trend  
    
B cell populations (%)    
 Naive Unchanged  Not determined 
 Transitional Unchanged   
 Memory Unchanged Similar Not determined 
 Regulatory Unchanged   
 Plasma Trend    
 GzmB+ B cells  Unchanged Not determined 
    
Inhibitory profile    
 CD32b Similar   
 BANK1 Trend  Trend  Trend  
 CD1d  Unchanged Similar 
 CD5 Trend    
 
Table 1.2. Comparison in B cell phenotypic profiles between tolerant kidney patients, patients under 
immunosuppression with stable kidney graft function, patients under immunosuppression with deteriorating 
kidney graft function and healthy volunteers. The table is the summary of observations in kidney transplant 
patients from different clinical studies
136,137,148,149
. The conventional immunosuppression therapy consists of 
calcineurin inhibitors and corticosteroids combined with azathioprine or mycophenolate mofetil (the differences 
in therapy between the different clinical studies are rather small). 
 
The expression of GzmB by B cells is not accompanied by perforin expression, as it is the 
case with T cells and natural killer cells, and is regulated by IL21. Activation of human B 
cells by IL21 and BCR or TLR engagement in the presence of CD40 ligation results in their 
differentiation into PCs. However, in the absence of CD40 ligation they differentiate into 
GzmB-expressing B cells
150–152
, which are phenotypically and functionally distinct from B10 
cells
151,153
. Stimulation of murine B cells with various B cell activators in combination with 
IL21 did not give expression of GzmB
154
. Hence, mouse models are unlikely to provide more 
insight into the physiological and pathological relevance of GzmB expression in human B 
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cells. But the peripheral blood B cells in a rat model of cardiac allograft tolerance displayed a 
very similar inhibitory profile as the B cells in the tolerant kidney transplant patients
149
: 
expression of GzmB, increased expression of BANK1 and IL21, and decreased ratio of 
CD32a/CD32b. So this rat model can be of use as surrogate to study function and therapeutic 
potential of B cells in transplantation tolerance. 
Operationally tolerant patients display a reduced number of circulating PCs compared to 
stable kidney graft patients who are still under immunosuppression. Genetic analysis showed 
that B cells of tolerant patients had a lowered expression of anti-apoptotic genes and a 
lowered expression of transcription factors PRDM1, IRF4 and XBP1 which are implicated in 
the end step of differentiation into PCs
148
. In an in vitro two-step culture model of B cell 
differentiation
155
, the B cells from tolerant patients displayed an increased susceptibility to 
apoptosis in the late step of differentiation into PCs compared to the stable graft patients 
under immunosuppression
148
. Figure 1.5 gives a schematic overview of the unique B cell 
profile in tolerant kidney transplant patients. 
 
 
Figure 1.5. B cell phenotypic profile in operationally tolerant kidney patients.  
TF: transcription factor. 
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Whether the Breg phenotype observed in operationally tolerant kidney transplant patients is 
the cause or the result of graft survival without immunosuppression remains to be determined. 
Evidence of a regulatory role of B cells in transplantation tolerance also raises questions about 
the impact of B cell-depleting therapies in transplant recipients. These agents might affect the 
induction and function of Bregs and potentially have detrimental effects on long-term graft 
outcomes. A clinical trial with renal transplant patients has shown an increased risk for acute 
cellular rejection following depletion of B cells by treatment with rituximab prior to 
transplantation, which could be due to a loss of Bregs
156
. 
Operational tolerance is more frequently reported in liver transplantation (immunosuppressive 
drugs can be completely withdrawn in up to 20 % of liver transplant recipients
157
). But B cells 
from tolerant liver transplant recipients do not harbour the inhibitory profile observed in 
tolerant kidney transplant patients. The tolerant liver transplant individuals exhibit 
significantly greater numbers of circulating potentially Treg subsets (CD4
+
CD25
+
 T cells and 
Vδ1+ T cells) than either non-tolerant patients or healthy individuals. And they exhibit a gene 
expression signature characterized by up-regulation of genes associated with γδ T cells and 
natural killer receptors, suggesting a role γδ T cells and natural killer cells in the maintenance 
of liver allograft tolerance
157
. Hence, the process of transplant tolerance might depend on the 
organ that is being transplanted. 
1.5. Need for better medicines to treat immune disorders and transplant rejection 
Current immunosuppressive drugs or agents used in immunotherapy have improved the life 
expectancy of patients, but, unfortunately, they also exhibit important toxic side effects due to 
their mechanism of action and their necessary chronic use in combination. Their non-selective 
activity causes immunodeficiency in the patient, resulting in increased susceptibility to 
infections and decreased cancer immunosurveillance. Immunosuppressive drugs can interact 
with other medicines and hereby affect their metabolism and action. 
The scale of the global drug-markets is gigantic and hits several US$ billions in annual sales 
and spending (for instance, a study in 2007 suggested that worldwide market of drugs used for 
the prevention of organ allograft rejection was US$ 6.6 billion
158
). In spite of the increasing 
levels of investments in pharmaceutical research and development, the output of new 
molecules and biologicals entering clinical development and reaching the market is 
disappointingly low
159,160
. It is clear that in drug discovery one approach does not fit all and 
that the strategies for screening to identify new drug compounds are constantly evolving. 
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Also, many major barriers to the development of new therapeutics are not scientific, but rather 
logistical, financial and procedural ones
158
. 
The majority of the marketed immunotherapeutic drugs are focused on controlling the activity 
of T cells (e.g. calcineurin inhibitors [cyclosporine A, tacrolimus]; mTOR inhibitors 
[sirolimus, everolimus]; co-stimulation blocking antibodies [belatacept, abatacept] or CD3 
antagonistic antibody [muromonab]) while it is becoming clear that B cells contribute to the 
pathogenesis of various immune disorders and to transplant rejection. Only a few molecules 
against B cells, mainly biologics, are available or under development. Strategies of B cell 
therapeutics comprise: 1) targeting B cell-specific surface markers, 2) depleting key survival 
factors, 3) disrupting critical intercellular interactions or 4) inhibiting crucial intracellular 
functions or signalling.  
1.5.1. Targeting B cell-specific surface markers 
Rituximab is a chimeric mouse-human monoclonal Ab directed against the surface protein 
CD20, an activated glycosylated phosphoprotein expressed on the surface of all B cells, but 
not on either early pro-B cells and PCs. Rituximab is very successful in depleting CD20-
expressing (normal and pathological) B cells and is therefore used to treat diseases 
characterized by overactive, dysfunctional or excessive numbers of B cells. However, PCs 
and memory B cells remain untouched. Rituximab has proved its therapeutic value in the 
treatment of several B cell malignancies and of AIDs such as RA and MS (but not in SLE). 
Some adverse events are associated with the use of rituximab: mild to moderate infusion 
reactions, higher incidence of infections, neutropenia and development of human anti-
chimeric Abs
161
. Nonetheless, the efficacy and success of rituximab has led to some other 
anti-CD20 monoclonal Abs being developed: ocrelizumab, ofatumumab and obinutuzumab. 
Epratuzumab is a fully humanized Ab directed against CD22 (also known as Siglec-2), a B 
lymphocyte-restricted type I transmembrane sialoglycoprotein (a combination of sialic acid 
and glycoprotein) of the Ig superfamily. CD22 is expressed at low levels on immature B cells 
and at higher levels on mature IgM
+
, IgD
+
 B cells whereas it is absent on differentiated PCs. 
The antigen is also found highly expressed on most malignant mature B cells. The exact 
mechanism of action of CD22 is not entirely clear, but it is an inhibitory co-receptor that 
negatively regulates BCR signalling, hereby preventing overactivation of the immune 
system
162
. Promising results have been obtained with epratuzumab in clinical trials with SLE-
patients
106
. Clinical trials are now ongoing to assess its long-term safety and efficacy. 
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Daratumumab is a human monoclonal antibody that specifically targets CD38, a type II 
transmembrane glycoprotein that is highly expressed on PCs and multiple myeloma cells, but 
weakly expressed on other lymphoid cells, other myeloid cells and non-haematopoietic cells. 
Clinical trials show encouraging data for daratumumab in the treatment of refractory multiple 
myeloma through its capacity to substantially deplete malignant PCs
163
. And the hope is that 
this agent can be used in an even wider range of blood cancers
164
. Data on the efficacy of 
daratumumab in patients with AIDs are not yet available. 
Alemtuzumab is a drug used in the B cell chronic lymphocytic leukemia (B-CLL), cutaneous 
T cell lymphoma and T cell lymphoma under the trade names Campath, MabCampath and 
Campath-1H, and in the treatment of MS as Lemtrada. It is also used in some conditioning 
regimens (in induction therapy for instance) for bone marrow transplantation, kidney 
transplantation and islet cell transplantation
165
. It is a monoclonal Ab that binds to CD52, a 
protein present on the surface of mature lymphocytes, but not on the stem cells from which 
these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing 
lymphocytes are destroyed, causing profound lymphocyte depletion. A complication of 
therapy with alemtuzumab is that it significantly increases the risk for opportunistic 
infections, in particular, reactivation of cytomegalovirus. An important side-effect of 
alemtuzumab therapy is the significant increase in circulating BAFF
166
 which might cause an 
increased frequency of Ab-mediated rejection or the development of (B cell-mediated) 
autoimmunity, e.g. thyroid AIDs, immune thrombocytopenia, Goodpasture syndrome are 
substantial adverse events associated with alemtuzumab treatment
167
. The levels of circulating 
BAFF can be controlled by using belimumab. 
1.5.2. Depletion of key survival factors 
Belimumab, a fully human anti-BAFF monoclonal Ab, specifically recognizes and inhibits the 
stimulatory activity of BAFF. Atacicept is a TACI-Ig fusion protein that neutralizes both 
BAFF and APRIL. Local and systemic overexpression of BAFF and APRIL is implicated in 
the pathogenesis of several AIDs including MS, SLE and RA
108
. This can be treated by 
administration of belimumab or atacicept. In clinical trials with SLE and RA patients, 
atacicept seemed to be well tolerated, but may be associated with injection-site reactions. 
However, increased inflammatory activity in the “ATAMS” (ATAcicept in Multiple 
Sclerosis) trial led to the suspension of atacicept trials in MS. Reasons for the unexpected 
increase in disease activity are unknown, but are under investigation
108
. 
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1.5.3. Disruption of intercellular interactions 
Abatacept and belatacept are fusion proteins composed of the Fc region of the 
immunoglobulin IgG1 fused to the extracellular domain of CTLA4 and bind to the CD80 and 
CD86 molecule, blocking the interaction between CD80/86 and CD28 co-stimulatory 
pathways. They are used to treat AIDs, like RA, by suppressing T cell function. Belatacept is 
also approved for use in organ transplantation. 
1.5.4. Inhibition of intracellular functions or signalling 
Small molecules inhibiting various BCR-associated kinases display encouraging clinical 
effects. Ibrutinib, an orally administered, covalent inhibitor of BTK, delivered a breakthrough 
in the treatment of B cell malignancies including mantle cell lymphoma, CLL, diffuse large B 
cell lymphoma and multiple myeloma. Ibrutinib or other BTK-inhibitors might show potential 
in the treatment of AIDs like RA and SLE. Clinical trials with fosfamatinib (targeting SYK) 
and idelalisib (targeting PI3Kδ) are ongoing28. But it must be emphasized that the „BCR 
inhibitors‟ probably target multiple pathways interconnected with BCR, e.g. chemokine- and 
integrin-signalling
28
. 
Bortezomib is a potent, selective small molecule inhibitor of the mammalian 26S proteasome, 
a large protein complex that degrades misfolded proteins, cell-cycle regulatory proteins, 
transcription factors and inhibitory molecules in order to maintain cellular homeostasis. 
Bortezomib is an N-protected dipeptide (pyrazinoic acid, phenylalanine and leucine with a 
boronic acid instead of a carboxylic acid). The boron atom in bortezomib binds the catalytic 
site of the 26S proteasome with high affinity and specificity and inhibits its proteolytic 
activity. Inhibition of proteasome activity results in the accumulation of misfolded proteins 
and affects multiple signalling cascades within the cell and sensitizes cells to programmed cell 
death. Rapidly dividing tumour cells appear to be more sensitive to proteasome inhibition. 
Moreover, bortezomib appears to increase the sensitivity of cancer cells to traditional anti-
cancer agents (e.g., gemcitabine, cisplatin, paclitaxel, irinotecan, and radiation). In clinic, 
bortezomib is used for treatment of relapsed multiple myeloma, a cancer of PCs. Bortezomib 
possesses also apoptosis-inducing activity against non-transformed PCs
168,169
. The clinical 
potential of bortezomib in transplantation (to treat Ab-mediated rejection 
169–171
) and AIDs 
(e.g. SLE
100,172
) is under investigation. Gastro-intestinal effects and asthenia (weakness) are 
the most common adverse events, but bortezomib has also been associated with peripheral 
neuropathy. 
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A visual overview of the prominent co-stimulatory and -inhibitory (cell surface) molecules is 
given in figure 1.6 together with the immunomodulatory therapeutics that target them. 
 
 
Figure 1.6. Illustration of prominent co-stimulatory/-inhibitory molecules and (B cell-specific) immuno-
modulatory therapeutics. 
 
Over time, tremendous progress has been made in understanding the mechanisms of immune 
responses. The challenge remains to selectively interfere with undesired, harmful immune 
responses responsible for autoimmunity or transplant rejection while keeping a flawless 
response to infectious agents. 
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Chapter 2  : Aim of the study 
Considering the dramatic numbers of people who suffer from an AID, or have a transplanted 
organ or are on the waiting list for a transplant, there is an urgent need to develop new 
medicine to cope with the undesired immune responses. It is well-established that B cells play 
a substantial role in the pathogenesis of many AIDs and in the rejection of transplants. Still, 
there are only a few B cell-specific immunomodulatory agents, mainly biologics like 
monoclonal Abs, available in the clinic. Despite their great specificity, the biologics are 
limited in their therapeutic actions that usually comprise the neutralization of pathogenic Abs 
or the depletion of certain subsets of B lymphocytes via binding with B cell-specific surface 
markers. Due to their size, biologics cannot cross the cell membrane and, hence, cannot 
influence directly intra-cellular processes and signalling pathways. B cells contribute to 
immune responses not solely by producing Abs, but also by communicating with distant and 
adjacent Th cells in order to orientate them in their actions. The direct communication 
between a B lymphocyte and a neighbouring Th cell happens by binding of receptors with 
their matched ligands on the cell surface. Receptor-ligand binding triggers signalling 
processes that lead to an alteration in behaviour (either activation or suppression in activity) 
of the interacting cells. The expression of the various cell membrane receptors and ligands 
reflect the cell‟s activation or regulatory status and can be increased or decreased in response 
to (micro-) environmental conditions leading to an altered sensitivity for cellular interplay. 
Relevant (new) targets in the B cell activation pathway can be identified when focussing on 
changes in expression of activation and co-stimulatory molecules on the B cell‟s surface. 
Subsequently, these identified targets can advance the understanding of B cell regulation as 
well as the creation and/or discovery of improved or even first-in-class medicines for more 
fine-tuned therapeutic intervention. 
In this project, we aimed to set up a B cell screen whereby the expression of cell surface 
markers forms the read-out in order to identify potential novel targets in B cell activation 
signalling pathways and to test new small molecule inhibitors for possible modulatory effects 
on B cell activation. 
For the establishment of the in vitro B cell screen, we needed to select and implement a 
robust, physiologically relevant B cell activation model. Keeping in mind that reproducibility 
and stability are essential for repetitive and large-scale screening, we examined several 
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immortalized human B cell lines for their responsiveness, as determined by the expression of 
several relevant cell surface markers, upon stimulation with the stimulator that was selected 
for having the broadest immunostimulatory effects on human primary B cells. The B cell line 
with the most similar expression profile to that of primary B cells was taken as a reliable, 
homogeneous substitute of the primary B cell. 
Afterwards, a lentiviral vector-based RNA interference library was screened on the 
established human B cell activation model in order to identify critical B cell genes coding for 
potential new targets involved in B cell activation. To maintain the idea of a first line 
screening assay, the read-out consisted of analyzing the expression of two cell surface 
markers with an important role in B cell - Th cell interactions. 
The identified candidate targets of the lentiviral vector library were further validated and 
characterized for their specificity, selectivity and druggability by means of in vitro phenotypic 
screens and of in vivo studies using commercially available small molecule inhibitors and by 
the generation of animal models with specific genetic deletion of the candidate target. 
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Chapter 3 Comparative in vitro immune stimulation analysis of primary 
human B cells and B cell lines 
 
The selection and implementation of a robust, physiologically relevant B cell activation model 
is published in Journal of Immunology Research: 
Van Belle K, Herman J, Boon L, Waer M, Sprangers B, Louat T. Comparative in vitro 
immune stimulation analysis of primary human B cells and B cell lines. J Immunol Res. 
2016;2016:5281823. doi: 10.1155/2016/5281823. PMID:28116319 
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Chapter 4 : Detection of potential new B lymphocyte targets using RNAi 
screening on ODN2006-stimulated Namalwa 
4.1. Introduction 
The developed in vitro immunoassay with ODN2006-stimulated Namalwa cells, as previously 
described, may be suitable to serve as a robust first line screening to identify potential B cell 
active compounds or to elucidate mechanisms of action of known immunosuppressive drugs. 
However, there is not an established pharmacological agent available for every target-
molecule encoded in the human genome. Furthermore, small molecule agents are commonly 
not specific for one target, but can display off-target effects at a similar or lower potency. 
Specific inhibition of a single target can be obtained via genetic silencing. RNA interference 
(RNAi) is a cellular mechanism that decreases the function of a gene through the degradation 
of its associated messenger RNA (mRNA). The introduction of short hairpin RNA (shRNA), 
an artificial RNA molecule with a tight hairpin turn, into mammalian cells through infection 
with replication-incompetent lentiviral vectors allows for stable integration of shRNA and 
long-term inhibition of the targeted gene
173
. 
Kinases are interesting targets for the development of therapeutic agents, because they 
catalyze phosphorylation, a process wherein phosphate groups are transferred from high-
energy phosphate-donating molecules, e.g. ATP, to specific substrates such as a protein, a 
lipid, a carbohydrate or an amino acid. The phosphorylation state of a molecule can affect its 
activity, reactivity, and its ability to bind other molecules. In eukaryotic cells, kinases are 
organized in signalling cascades which are typically initiated by various receptors which 
further pass their signals through various downstream effectors and regulate many essential 
cellular processes. Aberrant regulation of kinases plays a causal role in many diseases ranging 
from cancer to inflammatory diseases, diabetes, and infectious diseases
174–177
. 
The MISSION LentiExpress Human Kinases library is a broad library of lentiviral vectors 
carrying specific shRNA sequences targeting 501 human protein kinases and was selected to 
perform the genetic knock-out studies in order to identify new potential targets in B cell 
activation pathways and to gain more insight in the regulation of B cell activation. 
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4.2. Materials and methods 
4.2.1. Pharmacological reagents 
Following agents were tested for their effects in functional in vitro assays: HS38, IC261, 
NVP-BHG712 from Sigma-Aldrich (Diegem, Belgium); OSU-T315 from CalBiochem, 
Merck Millipore (Overijse, Belgium); Ki8751 and ML281 from Tocris Bioscience (Bristol, 
United Kingdom). 
4.2.2. Lentiviral shRNA human kinase library 
MISSION
®
 LentiExpress
TM
 Human Kinases library from Sigma-Aldrich (Diegem, Belgium) 
contained 3.200 different lentiviruses carrying shRNA sequences targeting 501 human protein 
kinase genes. Each gene was represented by a clone set that consisted of 3 to 10 individual 
constructs targeting different regions of the gene sequence. The lentiviral particles were 
provided in a pre-arrayed set ready-to-use format in 96-well plates with 5 000 transfection 
units per well. In addition to the kinase shRNA particles, each plate included positive and 
negative controls to monitor the transduction efficiency. The puromycin-resistance gene 
within the vector constructs allowed selection of the successfully transduced Namalwa cells 
by the antibiotic puromycin. 
Transduction of Namalwa cells, suspended in antibiotics-free DMEM-medium with 10 % 
FCS, with the lentiviral constructs was performed at a multiplicity of infection of 10 (5 000 
transfection units per 500 cells) in the presence of 8 µg/mL protamine sulphate (Leo pharma, 
Lier, Belgium) to increase transduction rates. After 3 days of incubation, puromycin (0,25 
µg/mL, InvivoGen, Toulouse, France) was added and a further incubation of 10 days gave an 
appropriate cell number of transduced Namalwa cells. Thereafter the Namalwa cells 
underwent stimulation with TLR9 agonist ODN2006 (Invivogen, Toulouse, France) for 24 
hours and were then analysed by flow cytometry (Figure 4.1). 
 
 
Figure 4.1. Screening of the lentiviral shRNA human kinase library on human B cell line Namalwa. 
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4.2.1. Flow cytometry 
FITC-labelled antibody to CD70 from Becton Dickinson Biosciences (Erembodegem, 
Belgium) and allophycocyanin (APC)-labelled antibody to CD80 from BioLegend (ImTec 
Diagnostics N.V., Antwerp, Belgium) were used for flow cytometric analysis of the lentiviral 
human kinase library on a Becton Dickinson FACSCanto
TM
 II apparatus. 
PE- or PE/Cy5-labelled antibodies to CD70 and CD80 from BioLegend (ImTec Diagnostics 
N.V., Antwerp, Belgium) were used for flow cytometric analysis of small molecule inhibitors 
by a 3-colour Becton Dickinson FACSCalibur
TM
 apparatus. 
4.2.2. Characterization of pharmacological reagents 
Pharmacological reagents were tested at different concentrations within the range of 0.0001 to 
10 µM in several functional in vitro assays: flow cytometry on Namalwa cells, human B cell 
IgG assay, MLR and cytotoxicity assays on cell lines Jurkat, Namalwa (both from European 
Collection of Cell Cultures, ECACC, England), RPMI 1788 and RAW264.7 (both from 
Global Bioresource Center ATCC, USA). The assays were performed as previously described 
(See „Materials and methods‟ in Chapter 3). 
4.3. Results 
4.3.1. Selection of read-out parameters for library screening 
For the screening of the large LentiExpress Human Kinases library, it was decided to restrict 
the read-out to two cell surface markers, because analysis of more markers would complicate 
the processing of all data and would impair the concept of a first line screening. The 
expression of various markers on naive and on ODN2006-stimulated Namalwa cells were 
discussed previously and represented in Figures 1 and 2 of article in Chapter 3.  
CD69 was not suited as read-out parameter, because on Namalwa cells it had a low base-line 
expression with only a limited increase after stimulation with ODN2006. Although CD40 
showed already a strong base-line expression on human peripheral B cells and on Namalwa 
cells, it gained a strong further increase after stimulation. However, CD40 was not selected as 
read-out parameter for the shRNA KO experiments, because in a second stage after the initial 
screening of the library we would like to rely on agonistic CD40 antibodies for B cell 
activation. The expression of CD70, CD80, CD83 and CD86 augmented well on peripheral B 
cells and Namalwa cells in response to ODN2006. Hereby, the up-regulation in expression of 
CD70 was more pronounced on Namalwa cells than on peripheral B cells. CD86, on the other 
hand, was more strongly induced on peripheral B cells. CD80 and CD83 increased more 
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uniformly in expression on Namalwa cells than on peripheral B cells. So far, there is only 
limited knowledge about the signalling pathways upon CD70 and CD80/CD86 triggering. 
Simultaneously with detecting new targets in B cell activation, the screening of the lentiviral 
vector shRNA library may provide interesting information about kinases involved in inducing 
or controlling the expression of CD70 and CD80/CD86 on B cells. Although CD70 and 
CD80/CD86 are not exclusively expressed by B cells, they are pragmatic indicators for the B 
cell‟s activation status. On Namalwa cells CD80 showed a more pronounced and less diffuse 
up-regulation in expression than CD86 upon ODN2006 stimulation, which is more convenient 
for the detection of inhibition in expression. Hence, CD80 was selected together with CD70 
as phenotypic read-out parameters for the initial screening of the lentiviral vector shRNA 
library. 
4.3.2. Detection of protein kinases with a possible role in B cell activation 
Electroporation or lipid transfection using transfection reagents such as Lipofectamine
®
 
RNAiMAX (Invitrogen
TM
, Thermo Fisher Scientific, Niederlebert, Germany) and HiPerFect 
Transfection Reagent (Qiagen, Antwerp, Belgium) were not effective to achieve gene 
silencing in human peripheral B cells, nor in Namalwa cells. The lentiviral particles of 
MISSION
®
 LentiExpress
TM
 shRNA libraries (Sigma-Aldrich, Diegem, Belgium) effectively 
transduced Namalwa cells. Using this method, a permanent silencing of the targeted gene can 
be achieved through the stable integration of the viral vector, encoding specific shRNA 
sequences, into the host genome. Transduced Namalwa cells were then stimulated by 
ODN2006 for 24 hours and flow cytometric analysis on markers CD70 and CD80 was 
performed. If the knock-out of a certain protein kinase led to an inhibition in up-regulation of 
CD70 and of CD80, it was hypothesized that this protein kinase may play an important role in 
B cell activation. The LentiExpress
TM
 library provided 3 - 10 shRNA clones per kinase target 
and we relied on the reproducibility between the different shRNA clones targeting the same 
kinase to refine the list of potential candidates. Figure 4.2 shows a global representation of the 
library screening. Up to now, the human kinome contains 538 protein kinase genes
178
 of 
which 501 are targeted in the lentiviral shRNA human kinase library. 
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Figure 4.2. Screening of the lentiviral shRNA human protein kinase library 
 
4.3.2.1. Lethal kinases 
Five hundred and one kinases were evaluated in our screening and the inhibition of 101 
protein kinases in the library proved to be lethal for Namalwa cells. Amongst them there were 
several kinases which have been demonstrated to be essential for B cell‟s survival (e.g. BTK 
and BLK) or for the cellular viability in general (e.g. cyclin-dependent kinases (CDKs), 
glycogen synthase kinase 3 beta (GSK3β), IκB kinases beta, gamma and epsilon (IKK-β/γ/ε), 
several MAP2Ks and MAP3Ks). Quite surprising at first notion, zeta-chain associated protein 
kinase 70 kDa (ZAP70) proved to play a role for Namalwa‟s viability. The cytoplasmic Tyr 
kinase ZAP70 from the SYK family was originally described to be present in T cells and 
natural killer cells and to be committed to signalling pathways following TCR 
stimulation
179,180
. Afterwards, ZAP70 has been reported in normal mouse B lineage cells and 
in human normal and malignant B lymphocytes wherein it shows a redundant function with 
the related SYK during B cell development and activation
181,182
. 
Hence, the screen was able to detect several kinases out of the library that are described to be 
essential for the B cell‟s viability. This could also imply that our group of lethal kinase 
inhibition target kinases that have not yet been reported before as vital for the B cell and, 
hence, might be interesting new targets for B cell depletion. However, as the attention in the 
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present research went to targets that predominantly influence B cell activation and not B cell 
viability, we did not further concentrate on these targets. 
4.3.2.2. Non-lethal kinases without effect on CD70 and CD80 expression 
The silencing of 400 kinases was not lethal for Namalwa cells, but the majority of them, 318 
kinases in total, did not show a significant inhibition of the up-regulation of CD70 and CD80 
in response to ODN2006 stimulation. They were regarded as “non-active, non-lethal” kinases. 
The group of 318 “non-active” kinases included the known AKT1/2/3, FYN, LYN and SYK, 
which are positioned in the early events of signalling pathways that coordinate cellular 
proliferation, survival and metabolism. Silencing of their expression can probably be 
bypassed in order to maintain viability and metabolism. AKT1/2/3, FYN, LYN and SYK are 
not (closely) involved in the TLR9-signalling pathway, clarifying why the expression of 
markers CD70 and CD80 on Namalwa cells remained unaltered. 
4.3.2.3. Non-lethal kinases with effect on CD70 and/or CD80 expression 
Deletion of 82 non-lethal kinases decreased the up-regulation of CD70 and/or CD80. Hence, 
they are regarded as “active” kinases. Amongst these, blockade of 40 kinases inhibited only 
CD70, whereas 20 other kinases seemed to be involved only in CD80 expression, suggesting 
a (partially) different regulation in expression for these two markers. Finally, genetic 
suppression of 22 kinases led to the inhibition of the up-regulation of both CD70 and CD80. 
The initial focus to detect small molecule kinase inhibitors with immunosuppressive effects 
on human B cells was put on the latter 22 “candidate target” kinases. 
4.3.2.4. Candidate target kinases 
The shRNA suppression screen identified 22 kinases which may play a relevant role in broad 
B cell activation since inhibition of these kinases abrogated the ODN2006-induced up-
regulation of the surface molecules CD70 and CD80, both shown to be important in providing 
co-stimulatory signals for T and B cell activation. Remarkable was the diversity of the known 
biological processes in which the 22 candidate target kinases have been described to be 
involved, notably intracellular signal transduction, angiogenesis, cell shape, cellular adhesion 
and motility, mitosis and vesicle-mediated transport of the Golgi apparatus. This may indicate 
that many events and pathways intervene in the ODN2006 - CD70/CD80 activation axis. 
4.3.3. Validation of the candidate target kinases with small molecule drugs 
To validate the 22 “candidate target” kinases as interesting targets or new therapeutics, 
several in vitro experiments were performed using small molecules shown to inhibit them on 
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the protein level. For only 6 of the 22 “candidate target” kinases, small molecule inhibitors 
were reported in the literature (Table 4.1): casein kinase 1 δ (CSNK1D)183, death-associated 
protein kinase 1 (DAPK1)
184
, ephrin type-B receptor 4 (EPHB4)
185
, integrin-linked kinase 
(ILK)
186
 kinase insert domain receptor (KDR)
187
 and Ser/Thr kinase 33 (STK33)
188
. 
The screening assay was repeated with the available small molecule inhibitors to check their 
effect on CD70 and CD80 expression. Two compounds successfully inhibited the up-
regulation of CD70 and CD80, namely NVP-BHG712, targeting EPHB4, and OSU-T315, 
targeting ILK. Furthermore, the compounds were tested in the human B cell IgG production 
assay (wherein B cells were stimulated by ODN2006) and only OSU-T315 potently 
suppressed the IgG production in vitro. In human MLR (to analyse the effects on T cell 
proliferation), OSU-T315 showed a moderate activity while NVP-BHG712 displayed much 
more potency than it did in the B cell IgG assay. Both compounds showed moderate intrinsic 
cell toxicity in the WST-1 assays on human B cell lines Namalwa and RPMI1788, T cell line 
Jurkat, and murine macrophage cell line RAW264.7. 
 
Table 4.1. Small molecule inhibitors of the identified target kinases were tested at different concentrations, 
maximum 10 µM and minimum 0.0001 µM, in several in vitro experiments. The values are calculated averages 
of three independently performed experiments. (*) Flow cytometric analysis of CD70 and CD80 on Namalwa 
after 24 hours incubation with ODN2006 and small molecule inhibitor; (**) Human B cell IgG production assay; 
(***) MLR with human PBMCs; (
x
) WST-1 viability assay on human cell lines Jurkat, Namalwa and RPMI 
1788 and murine cell line RAW264.7; (
xx
) Product IC50 mentioned by the supplier. ( = Strong effect,  = 
Moderate effect,  = Weak effect). For the definition of weak, moderate or strong effect, see section “materials 
and methods”. 
 
Hence, only ILK-inhibitor OSU-T315 effectively suppressed the up-regulation of markers 
CD70 and CD80 (IC50 0.74 µM and 0.24 µM, respectively) and also impeded the IgG 
production by primary B cells (IC50 0.53 µM) with IC50-values comparable to the protein 
inhibition IC50-value of 0.6 µM. The moderate toxicity and moderate activity in MLR indicate 
Target Chemical
Product
IC50
Inhibition 
CD70
Inhibition 
CD80
IgG
B cell
MLR
WST-1 
Jurkat
WST-1 
Namalwa
WST-1 
RPMI 1788
WST-1 
RAW264.7
CSNK1D & E IC261 1 > 10 > 10 6.16 0.62 0.55 1.24 0.59 4.14
DAPK1 HS38 0.2 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10
EPHB4 NVP-BHG712 0.025 0.85 2.50 8.80 0.86 5.52 6.39 5.13 7.32
ILK OSU-T315 0.6 0.74 0.24 0.53 3.53 5.58 4.60 4.04 5.30
KDR Ki8751 0.0009 > 10 > 10 > 10 0.89 > 10 > 10 0.90 > 10
STK33 ML 281 0.014 > 10 > 10 > 10 > 10 > 10 > 10 > 10 > 10
IC50 (µM)
(**) (***) (x) (x) (x) (x)
Namalwa (*)
(xx)
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that inhibition of ILK rather selectively impacts on B cell activity. Hence, the role of ILK on 
B cell activity and its potential as B cell target warranted further and more profound research. 
4.4. Discussion 
The objective of the present chapter was to identify new B cell targets via first-line screening 
of a large lentiviral vector-based shRNA library on human B cell line Namalwa and to 
validate these by small molecule inhibitors. 
Kinases were chosen as class of target molecules to search for new B cell targets, because, 
firstly, they generate important signalling cascades for the regulation of the cell‟s metabolism 
and viability and, secondly, their catalytic activity in phosphorylation can be manipulated by 
pharmacological drugs.  
A lentiviral vector-based shRNA library containing lentiviral particles designed to knock-out 
permanently and efficiently the genes of 501 human protein kinases was screened. The 
screening revealed firstly a rough distinction between lethal and non-lethal protein kinases. In 
the lethal group, there were kinases which are known to be essential in (B) cell viability, like 
BLK, BTK, CDKs, GSK3β, IKKs, ZAP70 and several MAP2Ks and MAP3Ks. But there 
were also several unfamiliar kinases in the lethal group which have not been reported before 
as vital for the B cell. This information may contribute to the development of new and 
possibly more specific B cell-depleting drugs after further investigations. An interesting result 
of the screening is that SYK is classified in the “non-active” kinases while ZAP70 is placed in 
the “lethal” kinases. The redundancy of ZAP70 with SYK, as mentioned earlier, is apparently 
not applicable in Namalwa. Perhaps Namalwa does not express SYK and, consequently, 
ZAP70 acquires a substantial role in viability of Namalwa. So far there is no information 
available about expression of SYK in Namalwa cells. Western blot or PCR analyses have not 
been performed to investigate that issue. 
The focus of the research was to identify targets which influence B cell activation in order to 
find B cell immunomodulatory drugs. Hereby, the expression of cell surface markers CD70 
and CD80 was used as read-out for the library screening. The group of non-lethal kinases 
were subdivided in “non-active” kinases, meaning there was no effect seen on the markers 
CD70 and CD80, and “active” kinases, meaning the up-regulation of CD70 and/or CD80 
upon ODN2006 stimulation had been impeded when these kinases were deleted. It must be 
mentioned that the absence of any effect does not necessarily mean that the kinases do not 
have a function in the TLR9-mediated activation pathway of the B cell. Indeed, ODN2006 is a 
broad stimulator with diverse phenotypic effects on B cells and it may be that some kinases 
 
53 Screening of human protein kinase shRNA library 
are on a position in the signalling pathway that is not involved in CD70 and CD80 expression, 
but still play a role, for instance, in Ig or cytokine production. Throughout evolution, 
signalling cascades of kinases have gained a high degree of robustness, which is achieved 
through redundancy at various levels, like compensatory pathways and feedback loops
178
. 
Each of the shRNA clones in the library targets one specific kinase. But closely related 
variants of the targeted kinase, so-called isoforms, are not inhibited in expression and can 
compensate for the loss of the targeted kinase. Also non-isoform kinases can take over from 
the deleted kinase. Moreover, the importance of a kinase depends on cell or tissue type and on 
(micro-environmental) circumstances. 
The group of “active”, non-lethal kinases was divided further in three sub-groups: 1) only 
CD70 was affected, 2) only CD80 was affected, and 3) both CD70 and CD80 were affected. 
The fact that kinases were identified in all groups indicates that CD70 and CD80 have a 
(partially) different regulation for their expression. The sub-groups of kinases that affect the 
expression of only CD70 or of only CD80 can provide important information about the 
position and role of the kinases involved within the B cell‟s signalling pathway(s) and about 
the particular regulation of CD70 and CD80. For example, the “selective CD70 blockers” may 
be interesting because 1° the CD70 pathway is a promising one for immunology and immune 
deficiencies, 2° a more selective blockade may also be clinically safer and 3° the other 
“selective” blockers active on the CD80 pathway already have more competitors in clinical 
development (the whole collection of CD80/86 : CD28 interfering mAbs). 
The suppressive effect of a genetic KO or of a small molecule inhibitor may be located at 
various levels of the activation pathways (Figure 4.3). Antagonism at the level of ligand - 
receptor ligation (Figure 4.3 a) can abort the complete signalling pathway from the very 
beginning leading to a general non-responsiveness upon stimulation. Chloroquine is a weak 
base that perturbs the acidic pH in endosomes and lysosomes and is commonly used as an 
antagonist for endosomal TLRs
189
. Inhibition of key molecules like IRAKs, p38 MAPK, JNK 
and IKK-complex in the proximal signalisation from TLR9 to transcription factors (e.g. NF-
κB, IRFs, CREB, AP-1) can still have exhaustive consequences in the progress to B cell 
activation. The B cell can then be impeded in all or in several of its functions (Figure 4.3 b 
and b‟). In contrast, interference of more distal molecules downstream the signalling pathway 
can result in a more specific functional/phenotypic aberrance, but can still permit some space 
for redundancy and alternative pathways to preserve the functional activity/phenotype (Figure 
4.3 c, c‟, c‟‟ and c‟‟‟). Specific functional defects or restrictions appear through suppression 
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of molecules at the very distal or terminal position of signalling pathways (Figure 4.3 d, d‟, 
d‟‟ and d‟‟‟). 
 
Figure 4.3. ODN2006 - CD70/CD80 activation axis 
 
After the initial screening, we focused on the sub-group of “candidate target” kinases that 
altered both CD70 and CD80, because we assumed that these suppressing kinases may have 
the highest likelihood of profound in vivo effects. For 6 of the 22 “candidate target” kinases, 
small molecule inhibitors were available for further validation. From the small molecules 
available, only two pharmacological agents, NVP-BHG712 (active against EPHB4) and OSU-
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µM)
190
 makes it, in addition, an interesting chemical hit susceptible to further chemical 
improvements. 
It is quite striking that 4 of the 6 tested small molecule inhibitors did not confirm the 
suppression of markers CD70 and CD80. Several elements may explain this. First, it must be 
notified that for the library screening the Namalwa cells were incubated during 14 days with 
the shRNA lentiviral particles for obtaining successful transduction giving a complete 
abrogation of the kinase in question, while the small molecule inhibitors were incubated 
together with ODN2006-stimulated Namalwa cells for just 24 hours. This much shorter 
incubation time of the small molecules and a lower inhibitory efficacy of these molecules 
compared to the shRNA-mediated deletion could have impeded suppressive activity on CD70 
and CD80. Repetition of the screening with a pre-incubation of Namalwa cells with the 
inhibitors, especially the non-toxic inhibitors, over a longer timeframe prior to ODN2006-
stimulation might still reveal molecules with activity in the ODN2006-CD70/CD80 signalling 
axis. Next, the kinase selectivity and inhibitory activity of the small molecules are usually 
determined by cell-free in vitro kinase assays. Consequently, these molecules can be less 
active due to their pharmacokinetic or -dynamic properties or their inhibitory activity may be 
bypassed or compensated within the cellular context. In addition, the observed cytotoxicity of 
a few molecules can be caused by off-target effects. 
IC261, targeting both CSNK1D and CSNK1E, proved to be a cytotoxic molecule, as 
determined by the low IC50-values in WST-1 on human cell lines (less explicit on murine 
RAW264.7) and in MLR. CSNK1D has an important function in cell proliferation and is 
described to be overexpressed in choriocarcinoma and pancreatic carcinoma
191,192
. In the 
lentiviral shRNA library screening, the inhibition of CSNK1D did not result in death of 
Namalwa cells. Only the genetic KO of the highly related isoform CSNK1E was lethal for 
Namalwa. Like CSNK1D, CSNK1E has a role in regulating cell division and overexpression 
of CSNK1E is associated with various cancers (breast, ovary, lung, colon, bladder, kidney, 
prostate, salivary glands, etc.)
191
. The difference in outcome between the shRNA library and 
the in vitro assays might probably be due to IC261‟s inhibitory effects on CSNK1E, rather 
than on CSNKID. While potent in WST-1 and MLR, IC261 displayed a moderate effect in the 
B cell IgG assay. IgG-producing B cells are much less active in proliferation and possibly for 
that reason IC261 was less effective in B cell IgG assay. 
HS38 and ML 281, inhibitors of DAPK1 and STK33 respectively, were inactive in all the 
performed assays. The KDR-inhibitor Ki8751 was potent in MLR and was cytotoxic for 
RPMI 1788, but showed furthermore no activity. 
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In the previous chapter, several clinical immunosuppressants and pharmacological reagents 
with known molecular mechanism of action have been tested in vitro on ODN2006-activated 
Namalwa and were analysed through one-on-one analysis of cell surface markers CD40, 
CD69, CD70, CD80, CD83 and CD86 by flow cytometry (See Table 2 of article in chapter 3). 
In addition to what is already mentioned in the discussion of that chapter, it was afterwards 
noticed that several immunosuppressants showed a stronger suppressive activity on the 
expression of CD86 than of CD80. Moreover, moderately toxic immunosuppressants that 
displayed a strong inhibitory effect on the human B cell IgG production, showed on Namalwa 
cells a similarly potent inhibitory activity on the expression of CD86. This was observed with 
ibrutinib (BTK), LY-294 (PI3K), MK-2206 (AKT1/2/3) and AZD-5363 (AKT1/2/3). These 
data might indicate that there is a correlation between the IgG production and the expression 
of CD86, even though we tested a selected group of immunosuppressants. Although they are 
highly similar, the co-stimulatory molecules CD80 and CD86 may, nonetheless, differ from 
each other in their contribution to T cell responses and in their regulation of expression, as 
suggested in literature
59,60,193
. The characterization of clinical immunosuppressants and 
pharmacological reagents was actually performed after the complete screening of the 
lentiviral shRNA human kinase library which had CD70 and CD80 as read-out parameters. If 
it was known before the start of the shRNA library screening about this possible 
interrelationship between IgG production and CD86 expression, we could have replaced 
CD80 by CD86 as read-out parameter. 
Due to the very large size of the shRNA library, verification of genetic knock-out by western 
blot or by polymerase chain reaction (PCR) could not be performed. However, we relied on 
the reproducibility between the different shRNA clones targeting the same kinase to conclude 
whether a kinase did have a role in B cell immunology or not. 
In conclusion, the screening of the lentiviral shRNA human protein kinase library on 
ODN2006-stimulated Namalwa cells has proved its value through its ability to pick several 
kinases known to be essential for B cell‟s viability, but has also revealed several interesting 
outcomes that require further investigations. Our obtained data can form the initiation of a 
whole array of more profound studies leading to a better understanding about the roles and 
position of the different protein kinases in the B cell‟s functioning. 
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Chapter 5 Integrin-linked kinase as a candidate target in B cell activation 
5.1. Introduction 
The screening of the lentiviral human protein kinase shRNA library on TLR9-stimulated 
Namalwa cells gave 22 “candidate target” kinases that were presumed to have a role both in 
the B cell‟s ODN2006-CD70 and the ODN2006-CD80 activation pathways. The further 
validation was initially confined to only 6 of these “candidate target” kinases due to limited 
availability of small molecules described in the literature to inhibit these kinases on the 
protein level. Only two chemical inhibitors could potently suppress the expression of both 
CD70 and CD80 in ODN2006-stimulated human B cells as observed in the shRNA library 
screening. Because of the encouraging data that OSU-T315 gave in the functional in vitro 
assays (See table 4.1), we further concentrated on ILK as a potential new B cell drug target. 
ILK is an evolutionarily conserved and ubiquitously expressed protein in the focal adhesions, 
which are large macromolecular assemblies through which mechanical force and regulatory 
signals are transmitted between the extra-cellular matrix (ECM) and the interacting cell, and 
is assumed to play an essential role in the integrin-matrix interactions, in microtubule 
dynamics, and in some signalling pathways (e.g. AKT, GSK3β, Rac1)194. ILK is composed of 
three structurally distinct domains (Figure 5.1): an N-terminal ankyrin repeat domain (ARD) 
with five ankyrin repeats, a central pleckstrin homology-like domain (PH) and a C-terminal 
kinase-like domain. Structure-based alignment sequencing and crystallographic studies show 
that ILK displays an atypical protein kinase domain. However, the lack of key conserved 
residues is not sufficient to predict whether a kinase domain has catalytic activity or not, as it 
is the case with Ca
2+
/calmodulin-activated Ser/Thr kinase (CASK), an apparent pseudokinase 
with the capacity of phosphoryl transfer
195–197
. In skin, bone and central nervous system, ILK 
regulates processes that are related to cell adhesion, migration and proliferation. By contrast, 
cells of the immune and cardiovascular systems rely on the adaptor and “kinase” capabilities 
of ILK for maintenance of immune cell trafficking, cell survival, and tissue function. Hence, 
the precise cellular processes regulated by ILK are dependent on contextual cues (e.g. cell 
type, tissue, pathology like tumorigenic cells). The potential “kinase” activity of ILK is 
stimulated by integrins and soluble mediators, including growth factors and chemokines, and 
is regulated in a PI3K-dependent manner, Figure 5.1 (1), whereby ILK binds PIP3 via the PH-
domain. After its activation, ILK exerts control over several downstream effectors, in 
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particular AKT and GSK3β (2). ILK rather regulates the phosphorylation of AKT at Ser-473 
and hereby Rictor, a member of the mTORC2 complex (reckoned as PDK2), facilitates that 
phosphorylation event (3). In addition to its catalytic function, the C-terminal kinase-like 
domain of ILK also interacts with integrins, paxilin, parvins and various actin-binding adaptor 
proteins (4) hereby establishing a linkage of integrins (5) to the actin cytoskeleton. Via the N-
terminal ARD domain with ankyrin-repeats, ILK interacts directly with several key proteins 
like PINCH (6) (which recruits ILK to the focal adhesion sites and connects ILK via NCK2 
indirectly with growth factor receptors), ILKAP (7) (which negatively regulates ILK-
signalling) and membrane receptors like SPARC and T-cadherin (8) (which contribute to 
outside-in signalling, cytoskeleton reorganisation and activation of small GTPases). Small 
molecule OSU-T315 is expected to disrupt the interaction of AKT with its binding site on 
ILK (9). Additionally, ILK also localizes to the centrosomes where it might aid in the 
assembly of the mitotic spindle through its interaction with tubulins and tubulin-binding 
proteins
198
. 
 
Figure 5.1. A schematic representation of the ILK interactome, based on the picture from Paul C. McDonald et 
al.
199
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Whether ILK is a functional kinase remains a contentious issue and the exact function of ILK 
remains unclear due to its intrinsic kinase function that is not always easily detected or 
demonstrated. Following arguments from literature argue against ILK as a functional kinase: 
ILK-deficient murine fibroblasts, chondrocytes or keratinocytes did not show impaired AKT 
and GSK3β phosphorylation as analysed by western blot197,200. Analysis on the structure of 
human ILK showed that the catalytic domain of ILK lacks critical consensus sequences of 
Ser/Thr kinases. There is an ATP-binding pocket present, but the unusual structural 
arrangement enholds a strong clue that hydrolysis of ATP does not occur
201
. Thus, ILK cannot 
perform catalysis as a conventional kinase. On the other hand, following arguments from 
literature support ILK being a functional Ser/Thr protein kinase: Pure human ILK showed 
kinase activity in vitro using a peptide or protein substrate and could directly phosphorylate 
several substrates (AKT, GSK3β, MYPT-1, myelin basic protein, MLC-20 and αNAC)202. 
HEK-293 cells which were transfected with ILK-specific siRNA showed suppressed 
phosphorylation of AKT and of GSK3β203. Ablation of ILK in murine heart, skeletal muscle, 
nervous system or macrophages resulted in abrogated AKT phosphorylation as analysed by 
western blot
197
. Suppression of ILK in various types of human normal and malignant cells led 
to decreased phosphorylation of AKT and GSK3β190,199,202,203. In ILK-deficient thymic T cells 
from Lck-Cre
+ 
/ ILK
flox/flox
 mice there was a decrease in AKT phosphorylation compared to 
those from Lck-Cre
+ 
/ ILK
WT/WT
 mice in response to stimulation with CXCL12
204
, a 
chemokine with the ability to orchestrate directional migration of a wide spectrum of cells to 
selected tissues. As a bona fide protein kinase ILK may gain activity under very (tissue-) 
specific conditions (e.g. upon post-translational modification and/or allosteric 
activators)
197,202,205
. The relative contributions of its kinase and adaptor functions may depend 
on tissue- and stage-specific developmental requirements, as well as consideration of normal 
versus pathological conditions. 
In the field of oncology, several investigations were conducted on ILK. Elevated ILK protein 
levels and activity have been associated with the oncogenesis and tumour progression of 
many types of malignancies (prostate, ovary, breast, colon, pancreas, stomach and liver), 
indicating that ILK represents a potential target for new cancer treatments
199,206–209
. OSU-
T315 was described as a novel, orally bio-available ILK inhibitor with high in vitro potency 
against a panel of prostate and breast cancer cell lines. In an in vitro radiometric kinase assay, 
OSU-T315 displayed a dose-dependent inhibitory effect with an IC50 of 0.6 µM on the 
phosphorylation of myelin basic protein, a known ILK substrate, by immunoprecipitated 
human ILK
186
. OSU-T315 proved its in vivo anti-tumour efficacy as a single oral agent by 
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suppressing PC-3, a human prostate cancer cell line, in a xenograft tumour growth model in 
athymic nude mice at 50 mg/kg/day
186
. The anti-tumour effect was ascribed to induction of 
apoptosis in cancerous cells. 
Relatively recently, studies are focusing on the interplay of the ECM and the cytoskeleton in 
B cell signalling and activation, e.g. resulting into stronger interactions with other immune 
cells (the „immunological synapse‟), formation and function of BCR micro-clusters, in 
antigen internalisation and in availability of additional co-stimulatory signals. Hence, the 
cellular cytoskeleton is emerging as a key player at several stages of B cell activation, 
including the initiation of receptor signalling
28,210–212
. From that point of view ILK might 
influence the B cell‟s function via its central position in connecting the ECM with the actin-
cytoskeleton. Hence, the present study was undertaken to further substantiate the role of ILK 
in B cell biology by investigating the effects of compound OSU-T315 on human B cells and 
in in vivo tests and by selectively knocking out the ILK gene in the B cells of mice. 
5.2. Materials and methods 
5.2.1. Characterization of small molecule compound OSU-T315 
Primary human B cells were stimulated in vitro with 0.1 µM ODN2006 (InvivoGen, 
Toulouse, France), 1 µM resiquimod (Sigma-Aldrich, Diegem, Belgium) or with 91 µg/mL 
TNP-BSA (Biosearch technologies, Novato, California, USA) in the absence or presence of 
different concentrations of compound OSU-T315 (CalBiochem, Merck, Millipore, Overijse, 
Belgium) within the range of 0.0001 to 10 µM. Several read-out were used: cell surface 
markers expression at 24 hours analyzed by flow cytometry, cytokine production at 48 hours 
analyzed by AlphaLISA (Perkin Elmer, Zaventem, Belgium), cellular proliferation at 72 
hours using 
3
H thymidine (Perkin Elmer, Zaventem, Belgium) incorporation and IgG and IgM 
production at 1 week analyzed by AlphaLISA. These assays were performed as previously 
described (Van Belle K et al., J Immunol Res 2016, 2016:5281823; PMID: 28116319). 
5.2.2. Generation of a mouse line with B cell-specific deletion of ILK 
Female ILK
flox/flox 
mice with C57Bl6 background, wherein the ILK encoding gene sequence is 
flanked by LoxP, were generated by the research group of Prof. Dr. René St.-Arnaud (McGill 
University and Shriners Hospital for Children, Montreal, Canada) and were kindly provided 
by Prof. Dr. Christa Maes (KULeuven, Belgium). Male CD19
Cre/Cre
 mice with C57Bl6 
background, wherein the gene sequence encoding for the cell surface marker CD19 is 
replaced by the gene sequence encoding for the enzyme Cre recombinase, were kindly 
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provided by Prof. Dr. Jan Cools (KULeuven, Belgium). The male CD19
Cre/Cre
 mice and 
female ILK
flox/flox 
mice were placed in a breeding program to obtain offspring with a B cell-
specific deletion of ILK, the CD19
Cre/WT 
/ ILK
flox/flox 
mice. Animal care was according the 
guidelines for laboratory animals from the KULeuven and all experiments were approved by 
the Ethical Committee for Animal Science of KULeuven (ethical committee, P075-2010 and 
P107-2015). Through a genotypic approach with PCR and a phenotypic approach with flow 
cytometry, the mice with B cell-specific deletion of ILK, genotype CD19
Cre/WT 
/ ILK
flox/flox
, 
were identified and were selected for the in vivo proof of concept experiments. 
5.2.3. Identification of mice with B cell-specific deletion of ILK  
5.2.3.1. Genotypic approach with PCR 
PCR was used to genotype the newly bred mice. Lysis of a piece of the tail of each mouse 
was performed by overnight incubation at 55 °C with lysis-buffer (100 mM Tris-HCl at pH 
7.5, 200 mM NaCl, 0.5 % SDS and 1 mM EDTA) and proteinase K (0.16 g/L, Roche 
Diagnostics, Mannheim, Germany). A pellet of tail lysate was obtained after centrifugation 
and the supernatant was taken. Isopropanol was added to the supernatant and the DNA was 
collected. After drying, the DNA was solved in TE-buffer (10 mM Tris-HCl at pH 7.5 and 1 
mM EDTA at pH 8) and incubated overnight at room temperature for complete solubilisation. 
5.2.3.1.1. Identification of mice with CD19-Cre allele(s) 
Mice with a CD19-Cre positive genotype were identified with the SYBR Green dye-based 
real-time PCR (RT-PCR) amplification and detection method. The final concentrations of the 
components in the PCR-mix for CD19-Cre were as follows: 1x SYBR
® 
Green PCR master 
mix (Applied Biosystems, Halle, Belgium), 0.8 µM oligonucleotide primers and 1 µL of DNA 
sample for total volume of 20 µL. With the set of primers CD19-Cre sense (primer sequence 
5‟ GCGGTCTGGCAGTAAAAACTATC 3‟; Sigma-Aldrich, Diegem, Belgium) and CD19-
Cre anti-sense (primer sequence 5‟ GTGAAACAGCATTGCTGTCACTT 3‟; Sigma-Aldrich, 
Diegem, Belgium) there was only amplification of DNA when there is a CD19-Cre allele. 
PCR cycling was performed using the StepOnePlus RT-PCR System (Applied Biosystems, 
Halle, Belgium) with initial denaturation at 95 °C for 10 minutes, followed by 35 cycles of 95 
°C for 30 seconds, 58 °C for 30 seconds and 72 °C for 40 seconds, the final extension step 
was done at 72 °C for 3 minutes. The amplified DNA was separated on a 2 % agarose gel. 
After staining of the agarose gel with ethidium bromide the DNA bands were visualized with 
UV light. A band of 100 base pairs (bp) indicated the mice with a CD19-Cre allele. Mice with 
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homozygous CD19-WT genotype did not give a band on the agarose gel, as there was no 
DNA amplification. Distinction between the homozygous and the heterozygous CD19-Cre 
mice was done by flow cytometry (See paragraph 5.2.3.2.). 
5.2.3.1.2. Identification of mice with floxed ILK allele(s) 
The genotypic distinction between ILK
WT/WT
, ILK
flox/WT
 and ILK
flox/flox 
mice was done by 
PCR. The final concentrations of the components in the PCR-mix for floxed ILK were as 
follows: 25 U/mL GoTaq
®
 G2 Flexi DNA polymerase (Promega), 1x Green GoTaq
®
 Flexi 
buffer (Promega), 2 mM MgCl2, 200 µM dNTP‟s, 0.4 µM oligonucleotide primers and 1 µL 
of DNA sample for total volume of 25 µL. We used the set of primers ILK Jax sense (primer 
sequence 5‟ GACCAGGTGGCAGAGGTAAG 3‟; Sigma-Aldrich, Diegem, Belgium) and 
ILK Jax anti-sense (primer sequence 5‟ GCTTTGTCCACAGGCATCTC 3‟; Sigma-Aldrich, 
Diegem, Belgium) to identify the mice with a homozygous floxed ILK genotype (ILK
flox/flox
). 
PCR cycling was performed using the GeneAmp
®
 PCR System 9700 (Applied Biosystems) 
with the same program as for the identification of CD19-Cre allele(s). The amplified DNA 
was separated on a 2 % agarose gel. After staining of the agarose gel with ethidium bromide 
the DNA bands were visualized with UV light. The size of the wild type (WT) ILK allele was 
245 bp and of the floxed ILK allele was 270 bp. Mice that were homozygous for the WT ILK 
allele showed a DNA band of 245 bp. Mice that were homozygous for the floxed ILK allele 
showed a DNA band of 270 bp. Heterozygous ILK
flox/WT
 mice were identified by the 
observation of two DNA bands on the agarose-gel: a band of 245 bp from the WT allele and a 
band of 270 bp from the floxed allele. 
5.2.3.2. Phenotypic approach with flow cytometry 
5.2.3.2.1. Identification of homo- and heterozygous CD19-Cre mice 
Since CD19
Cre/WT
 (with one CD19-Cre allele) and CD19
Cre/Cre 
mice (with two CD19-Cre 
alleles) could not be distinguished from each other by separation of the PCR-products on 
agarose-gel, the distinction between CD19
WT/WT
, CD19
Cre/WT
 and CD19
Cre/Cre 
mice was done 
by flow cytometry on murine blood. Blood was taken from the newly bred mice by eye 
puncture. Murine blood cells were washed with cold PBS and were incubated 30 minutes at 4 
°C with FITC-labelled anti-murine CD19 (Biolegend, ImTec Diagnostics N.V., Antwerp, 
Belgium) and PE/Cy5-labelled anti-murine CD45R/B220 (Biolegend, ImTec Diagnostics 
N.V., Antwerp, Belgium). CD45R/B220, commonly used as a pan-B cell marker, was 
included in the double staining to allow visualization of B cells in the blood of mice with 
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lowered (heterozygous CD19-Cre genotype) or completely deleted (homozygous CD19-Cre 
genotype) expression of CD19. After staining, the blood cells were washed twice with cold 
PBS and incubated for 20 minutes at 4 °C with fixation/permeabilization solution (BD 
Cytofix/Cytoperm
TM
, BD Biosciences, Erembodegem, Belgium). After two washes with 
permeabilization/wash buffer (BD Cytofix/Cytoperm
TM
, BD Biosciences, Erembodegem, 
Belgium), the cells were suspended in cold PBS and analysed with the 3-color Becton 
Dickinson FACSCalibur apparatus. 
5.2.4. Protein detection and western blot analysis 
Single-cell suspensions of murine splenocytes were prepared by manual disruption from total 
spleen of an ILK wild type (WT) mouse (genotype CD19
WT/WT 
/ ILK
flox/flox
), an ILK knock-
out (KO) mouse (genotype CD19
Cre/WT 
/ ILK
flox/flox
) and of a hetero mouse (genotype 
CD19
Cre/WT 
/ ILK
flox/WT
) and highly purified B lymphocytes were isolated by 
immunomagnetic positive selection according to manufacturer‟s instructions (STEMCELL 
Technologies, EasySep
TM
 Mouse CD19 positive selection kit II, Grenoble, France). Cells 
were lysed and proteins were separated on NuPAGE
®
 Novex
®
 4-12 % Bis-Tris gel 
(Invitrogen
TM
, Thermo Fisher Scientific, Niederlebert, Germany) and electrotransferred onto 
polyvinylidene fluoride membrane (PVDF membrane, Invitrogen
TM
, Thermo Fisher 
Scientific, Niederlebert, Germany) and incubated with specific antibodies. Immunoreactive 
proteins were detected by Bio-Rad Imager (Bio-Rad laboratories N.V., Temse, Belgium) and 
normalized to the β-actin content. The used antibodies were: monoclonal rabbit anti-ILK 
(4G9; 1/1 000; Cell Signaling Technology
®
, Bioké, Leiden, The Netherlands), monoclonal rat 
anti-CD20 (AISB12; 1/500; Affymetrix
®
, eBioscience
®
, Vienna, Austria), anti-β actin (I-19; 
1/1 000, Santa Cruz Biotechnology, Heidelberg, Germany), polyclonal (goat anti-rabbit, 
rabbit anti-goat and rabbit anti-rat) Ig/HRP (Dako, Heverlee, Belgium). 
5.2.5. Mice deficient in mature B cells 
Homozygous mutant B6.129S2-Ighmtm1Cgn/J mice, also known as muMt-, lack mature B 
cells. There is no expression of membrane-bound IgM because a neomycin resistance cassette 
disrupted one of the membrane exons of the gene encoding immunoglobulin heavy chain of 
the class mu (IgM). Mutant animals with C57Bl6 background were purchased at The Jackson 
Laboratory (France). 
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5.2.6. ODN1826 in vivo assay 
Mice were stimulated subcutaneously with ODN1826 (InvivoGen, Toulouse, France; murine 
TLR9 agonist) at 60 µg/head. Naive control mice were injected with sterile PBS. Two hours 
post-stimulation blood was collected by eye puncture. Analysis of IL6 and TNFα in the 
plasma was done with the AlphaLISA murine IL6 and TNFα kit according to manufacturer‟s 
instructions (Perkin Elmer, Zaventem, Belgium). In case of treatment of mice with (small 
molecule) compound, which was administered 30 minutes before ODN1826-stimulation, the 
inhibitory effect was calculated with following formula: 
% inhibition =  
Analyte stands for the concentration of the analyte (ng/mL) contained in the sample. 
5.2.7. TNP-BSA in vivo assay 
ILK WT mice (genotype CD19
WT/WT 
/ ILK
flox/flox
), ILK KO mice (genotype CD19
Cre/WT 
/ 
ILK
flox/flox
) and ILK hetero mice (genotype CD19
Cre/WT 
/ ILK
flox/WT
) were stimulated with T 
cell-dependent antigen TNP-BSA (50 µg/head) solved in complete Freund‟s adjuvant ( 
Sigma-Aldrich, Diegem, Belgium) by injection, subcutaneously. Blood was collected by eye 
puncture before stimulation and on days 7, 10, 14, 21 and 28 post-stimulation. On day 28, the 
mice underwent for a second time stimulation with TNP-BSA (50 µg/head, solved in 
complete Freund‟s adjuvant) and blood samples were taken on days 35 and 42. 
Analysis of anti-TNP IgG and IgM in the collected sera was done by ELISA procedure with 
sheep anti-mouse IgG (H/L):horse radish peroxidise (HRP) and with goat anti-mouse 
IgM:HRP (both from Bio-Rad AbD Serotec, Oxford, United Kingdom), respectively. 
Peroxidase activity was detected by adding 3,3‟,5,5‟-tetramethyl-benzidine liquid substrate 
(Sigma-Aldrich, Diegem, Belgium). Reaction was stopped by adding 1 M HCl, forming a 
yellow reaction product. Absorbance was measured by the ELISA reader at 450 nM. 
5.2.8. TNP-Ficoll in vivo assay 
ILK WT mice (genotype CD19
WT/WT 
/ ILK
flox/flox
), ILK KO mice (genotype CD19
Cre/WT 
/ 
ILK
flox/flox
) and ILK hetero mice (genotype CD19
Cre/WT 
/ ILK
flox/WT
) were immunised 
intraperitoneally with T cell-independent antigen TNP-Ficoll (25 µg/head) solved in PBS. 
Blood was collected by eye puncture before stimulation and on days 5, 7, 10, 14 and 21 post-
stimulation. Analysis of anti-TNP IgM in the collected sera was done by ELISA procedure 
with goat anti-mouse IgM:HRP (Bio-Rad AbD Serotec, Oxford, United Kingdom). 
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Peroxidase activity was detected by adding 3,3‟,5,5‟-tetramethyl-benzidine liquid substrate 
(Sigma-Aldrich, Diegem, Belgium). Reaction was stopped by adding 1 M HCl, forming a 
yellow reaction product. Absorbance was measured by the ELISA reader at 450 nM. 
5.2.9. In vivo xeno-antibody assay with BHK-570 cells 
ILK WT mice, ILK KO mice and ILK hetero mice were stimulated with intraperitoneally 
injected baby hamster kidney (BHK) 570 cells (5.10
6
 cells in RPMI-medium, 200 µL/head; 
Global Bioresource Center ATCC
®
, USA) and the production of IgM and IgG against the 
hamster cells was analysed on days 3, 5, 7 and 10 post-immunisation. Naive ILK WT mice 
were included as a control group. For analysis of the IgM and IgG titer in the murine sera, 
5.10
5
 BHK-570 cells were dispatched per well in a 96-well V-bottom plate and 5 µL of serum 
sample was added. After incubation of 30 minutes on ice, BHK-570 cells were washed two 
times with PBS. Secondary antibody (goat anti-mouse IgM antibody-PE or goat anti-mouse 
IgG antibody-FITC, Biolegend, ImTec Diagnostics N.V. Antwerp, Belgium) was added and 
incubated for 30 minutes on ice and protected from light. After 3 washes with PBS, IgM and 
IgG were assessed by flow cytometry with the 3-color Becton Dickinson FACSCalibur 
apparatus. 
5.2.10. In vitro murine B cell activation assays 
Single-cell suspensions of splenocytes were prepared by manual disruption from total spleens 
of ILK WT mice, ILK KO mice and ILK hetero mice and highly purified B lymphocytes were 
isolated by immunomagnetic positive selection according to manufacturer‟s instructions 
(STEMCELL Technologies, EasySep
TM
 Mouse CD19 positive selection kit II, Grenoble, 
France). The purity of the isolated murine B cells was ≥ 95 % as analysed by flow cytometry. 
Splenic B cells were suspended at the desired concentration in complete DMEM culture 
medium and activated by 5 µg/mL LPS. The production of cytokines IL6 and TNFα was 
analysed 2 days post-stimulation and the proliferation rate was measured 3 days post-
stimulation. 
5.2.11. LPS survival assay 
ILK WT mice, ILK KO mice and ILK hetero mice were challenged intraperitoneally with 200 
µL LPS-solution of 0.150 mg/mL, 0.500 mg/mL or 1.500 mg/mL (30 µg LPS/head, 100 µg 
LPS/head or 300 µg LPS/head, respectively). Body weight and survival rate were followed up 
during 8 days. 
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5.2.1. Statistical analysis 
Statistical analyses for different experiments were performed using GraphPad Prism software 
and p values were calculated by two-tailed Student t-test. P values less than 0.05 are 
considered as significant. 
5.3. Results 
5.3.1. Assessment of the immunomodulatory activity of OSU-T315 on B cells 
5.3.1.1. OSU-T315 effectively inhibits in vitro B cell activation 
To investigate the potential role of ILK in the B cell‟s functions, several phenotypic in vitro 
experiments with compound OSU-T315 were performed on human primary B cells. 
First, we investigated the effects of OSU-T315 on human primary B cells that were stimulated 
by ODN2006. Analysis of the cell surface markers CD69, CD70, CD80 and CD86 
demonstrated that OSU-T315 was able to suppress in a dose-dependent manner the up-
regulation of markers CD69, CD70, CD80 and CD86. The IC50 was about 0.5 µM for each 
marker (Figure 5.2). 
 
 
Figure 5.2. Effect of OSU-T315 on activation and co-stimulatory markers after ODN2006 stimulation. Purified 
human primary B cells were stimulated with 0.1 µM ODN2006 and simultaneously treated with OSU-T315 at 
different concentrations and were analysed 24 hours later by flow cytometry. Graphs represent the data from 5 
independent experiments. 
CD70 CD80
CD69 CD86
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Also the production of IgG, IgM and IL6 in response to ODN2006 stimulation was 
significantly decreased when OSU-T315 was applied at concentrations between 0.1 - 1 µM 
(Figure 5.3 A, B and C, respectively). Similarly, OSU-T315 inhibited the proliferation of 
activated B cells with comparable efficacy (Figure 5.3 D). The IC50 value in the IgG assay 
was around 0.2 µM and in the IgM, IL6 and proliferation assays the IC50 values were around 
0.5 µM, as with the cell surface markers. 
 
Figure 5.3. Effect of OSU-T315 on the production of IgG (A), IgM (B) and IL6 (C) and on B cell proliferation 
(D). Highly purified human primary B cells were cultured in the presence of a range of stimuli (0.1 µM 
ODN2006, 1 µM resiquimod or 91 µg/mL TNP-BSA). IL6 was analysed after 2 days of incubation, proliferation 
was measured by 
3
H thymidine incorporation after 3 days of incubation and analysis of IgG and IgM was 
performed after 7 days of incubation. Graphs represent the data from 2 independent experiments. 
 
OSU-T315 was also investigated on human B cells stimulated with resiquimod, a synthetic 
agonist of TLR7/TLR8, or with TNP-BSA. The inhibition of the IgG and IgM production by 
OSU-T315 after stimulation with resiquimod was comparable to ODN2006 (IC50 values 0.3 
µM and 0.4 µM, respectively) (Figure 5.3 A-B). For IL6 the IC50 value was around 1 µM 
(Figure 5.3 C). OSU-T315 displayed less potency in the B cell proliferation assay (Figure 5.3 
D), but that was probably due to the fact that resiquimod is a relatively moderate stimulator of 
B cell proliferation (See Table 1 of article in chapter 3). Also resiquimod-induced up-
regulation of the cell surface markers was suppressed by OSU-T315 in a dose-dependent 
manner (data not shown). OSU-T315 inhibited TNP-BSA-triggered B cell proliferation 
A B
C D
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(Figure 5.3 D) with an IC50 value of 0.6 µM. Less inhibitory effect by OSU-T315 was noticed 
in the TNP-BSA-induced IgG, IgM and IL6 production, with IC50 values of 1.5 µM, 1 µM 
and 1 µM, respectively (Figure 5.3 A, B and C, respectively). TNP-BSA was not able to 
induce the cell surface markers (See Table 1 of article in chapter 3). 
5.3.1.2. OSU-T315 inhibits in vivo IL6 production induced by ODN1826 
The data from the phenotypic in vitro assays indicated that ILK may have a role in the 
activation of B cells. Next, we investigated the in vivo effects of OSU-T315 treatment on IL6 
and TNFα production after TLR9 stimulation with ODN1826 (the murine counterpart of 
ODN2006). Naive control mice and stimulated control mice were both treated with vehicle 
and upon stimulation a clear up-regulation in IL6 and TNFα production was observed in the 
stimulated control mice (p < 0.0001) (Figure 5.4). 
 
Figure 5.4. Effect of OSU-T315 on IL6 and TNFα production in vivo. Thirty minutes before TLR9 stimulation 
with ODN1826, C57Bl6 mice were treated orally with OSU-T315 at the indicated doses. The naive and 
stimulated control mice received vehicle. Five mice were included in each group. Two hours post-stimulation 
IL6 (A) and TNFα (B) were measured in the plasma. The graphs show data from one representative of the three 
independently performed experiments. 
 
The mice that were treated orally with OSU-T315 showed a significantly lower production of 
IL6 in the in vivo experiments (Figure 5.4 A). In contrast to the in vitro assay with human B 
cells, a clear dose effect of OSU-T315 was not seen in vivo over the range of doses tested (0.5 
mg/kg to 50 mg/kg). The average inhibition of IL6 production was 30 %. The absence of a 
dose effect could be due to IL6 production by (non-) hematopoietic cells that responded to 
ODN1826 stimulation, but were not affected by OSU-T315‟s activity. OSU-T315 did not 
influence the in vivo TNFα production upon ODN1826 stimulation (Figure 5.4 B). 
*
**
***
p = 0.0012
p = 0.0073
p = 0.0030
A B
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The preliminary results with OSU-T315 confirmed that ILK could be a promising target in the 
modulation of some B cell activity. To further validate ILK as a B cell target, we created mice 
with B cell-specific deletion of ILK. 
5.3.2. Investigation on the importance of ILK on B cell biology in vivo 
To investigate the significance of ILK in vivo, we created mice with B cell-specific deletion 
of ILK by means of the Cre/LoxP system. Cre recombinase enzyme, whose expression was 
under control of the CD19-promotor, excised the “floxed” ILK gene exclusively in the B 
lymphocytes. 
5.3.2.1. Identification of ILK WT, hetero and KO mice 
CD19 is a transmembrane protein on B lymphocytes that serves as a co-stimulatory molecule 
for amplifying proximal BCR signalling. It is described that a complete abrogation in 
expression of CD19 in mice causes defective late B cell differentiation and decreased Ab 
responses
213,214
. In human patients, CD19 deficiency not only causes common variable 
immunodeficiency, but also favours the development of autoimmunity
215
. For that reason, we 
preferred the mice with CD19
Cre/WT 
/ ILK
flox/flox 
genotype with a partial deletion of CD19 over 
the ones with
 
CD19
Cre/Cre 
/ ILK
flox/flox 
genotype with a complete deletion of CD19 as our mice 
with B cell-specific knock-out for research. By means of PCR and flow cytometry, we were 
able to select the mice of interest (Figure 5.5). Separation and visualisation of the PCR 
products of tail DNA on agarose gel permitted us to identify the ILK
WT/WT
 (band of 245 bp), 
ILK
flox/WT
 (bands of 245 bp and 270 bp) and ILK
flox/flox
 (band of 270 bp) mice (Figure 5.5 A). 
Flow cytometric analysis of cell surface markers CD19 and CD45R/B220 on blood samples 
of the earlier identified ILK
flox/flox
 mice (Figure 5.5 B) enabled us to determine homozygous 
CD19
WT/WT 
mice, homozygous CD19
Cre/Cre
 mice and heterozygous CD19
Cre/WT
 mice amongst 
the ILK
flox/flox 
mice. Mice with CD19
Cre/Cre 
genotype did not display CD19 on the outer surface 
of the B cells. Heterozygous mice still expressed CD19 on the outer surface of the B cells, but 
at a lower density compared to CD19
WT/WT
 mice which translated in lower mean fluorescence 
intensity (MFI). The similar percentages of gated CD45R/B220
+
 cells with equal MFI 
demonstrated that there was no loss in the B cell population in the CD19
Cre/WT
 and CD19
Cre/Cre 
mice compared to the CD19
WT/WT
 mice. 
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Figure 5.5. Identification of ILK WT, hetero, KO mice through PCR (A) and flow cytometry (B) and 
confirmation of B cell-specific deletion of ILK by western blot (C). (A) Amplified DNA from mouse tails was 
separated and visualized on a 2 % agarose gel to identify the floxed ILK genes: L, TrackIt
TM
 100 bp DNA 
ladder; WT, wild type ILK
WT/WT
; H, heterozygote ILK
flox/WT
; F, homozygote ILK
flox/flox
. (B) Blood from the 
homozygote ILK
flox/flox 
mice was double-stained with CD19 (FITC) and CD45R/B220 (PE/Cy5) to determine for 
homozygous CD19
WT/WT
, heterozygous CD19
Cre/WT
 and homozygous CD19
Cre/Cre
. (C) Western blot was 
performed on splenocytes and on splenic B cells from mice identified as being ILK wild type (WT; genotype 
CD19
WT/WT 
/ ILK
flox/flox
), ILK hetero (Het; genotype CD19
Cre/WT 
/ ILK
flox/WT
) or ILK knock-out (KO; genotype 
CD19
Cre/WT 
/ ILK
flox/flox
). 
 
B cell-specific deletion of ILK in ILK KO mice was confirmed by western blot analysis 
(Figure 5.5 C). High expression of ILK was observed in the splenocytes of WT (wild type; 
CD19
WT/WT 
/ ILK
flox/flox
), Het (hetero; CD19
Cre/WT 
/ ILK
flox/WT
) and KO (knock-out; 
β-actin
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ILK
Het KO WT Het KO WT KO WT
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Average 
values
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CD19
Cre/WT 
/ ILK
flox/flox
) mice, but ILK was not detected in the B lymphocytes of KO mice. 
Hetero mice showed a lower expression of ILK compared to WT mice. 
5.3.2.2. The in vivo production of IL6 and TNFα upon ODN1826 
stimulation is not influenced by the B cell-specific deletion of ILK 
In all three groups of ILK mice (ILK WT, ILK hetero and ILK KO), stimulation with 
ODN1826 resulted in a clear increase of IL6 and TNFα production. Under naive 
circumstances, all three groups of mice showed an average level of IL6 at 10
-5
 ng/mL and an 
average level of TNFα at 10-2 ng/mL. 
 
 
Figure 5.6. ODN1826 in vivo assay on mice with B cell-specific ILK deletion. IL6 (A) and TNFα (B) 
production was measured two hours post-stimulation in the plasma of ILK WT mice (blue, 3 mice), ILK hetero 
mice (green, 3 mice) and ILK KO mice (red, 3 mice). The graphics show data from one representative of the 
three independently performed experiments. 
 
After stimulation, there was no significant difference in the level of IL6 (Figure 5.6 A) and of 
TNFα (Figure 5.6 B) between the three groups of ILK mice. Neither a lowered expression nor 
a complete deletion of the ILK protein in the murine B lymphocytes led to a change in 
production of both pro-inflammatory cytokines. This could indicate that ILK may not be 
involved in B cell-mediated IL6 and TNFα production upon TLR9 stimulation in our model. 
A B
WT Hetero KO WT Hetero KO
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Figure 5.7. ODN1826 in vivo assay on B cell-deficient mice. IL6 (A) and TNFα (B) production was measured in 
the plasma of 3 B cell-deficient mice before ODN1826 stimulation and 2 hours post-stimulation. 
 
We used a strain of B cell-deficient mice (Ighmtm1Cgn/J) to examine if other immune cells 
besides B cells can be induced by ODN1826 to raise the level of IL6 and TNFα in the plasma. 
The animals showed a clear augmentation of both cytokines (Figure 5.7 A and B), 
demonstrating that B lymphocytes are not the main producers of IL6 and TNFα. For instance, 
T cells, macrophages and some non-immune cells such as muscle
216
 can secrete IL6 in 
response to stimulatory environmental conditions. Consequently, B cell-specific deletion of 
ILK might not have any notable influence on IL6 and TNFα production induced via TLR9. 
5.3.2.3. The Ig-production against TNP-BSA and TNP-Ficoll is not 
influenced by the deletion of ILK 
For triggering of in vivo Ig-production, we had to switch to TNP-hapten conjugate as 
stimulator, because we could not obtain an adequate induction of Ig-production with 
ODN1826. ILK WT, ILK hetero and ILK KO mice were immunised with TNP-BSA and the 
production of IgG and IgM was followed over time. This TNP-BSA in vivo assay has been 
carried out two times and a different outcome was obtained in the IgG production (Figure 
5.8). 
 
B
Pre-stim. 2 hours 4 hours 6 hours
A
Pre-stim. 2 hours
* *p = 0.0044 p = 0.0021
 
73 ILK as a candidate B cell target 
 
Figure 5.8. IgG production in mice with B cell-specific ILK deletion after TNP-BSA immunisation. Graphics 
display data of two independently performed experiments. The level of IgG was measured over time in the sera 
of ILK WT mice (blue, 8 mice), ILK hetero mice (green, 6 mice) and ILK KO mice (red, 8 mice). TNP-BSA 
challenges are indicated with reversed orange triangles. 
 
In the first experiment (left graphic), it was quite remarkable that ILK hetero mice had the 
highest anti-TNP IgG in their sera. On days 14, 21 and 28 after the first immunisation, there 
was a significant difference between ILK hetero mice and ILK KO mice (p = 0.0048, p = 
0.0188 and p = 0.0389, respectively), even if the increase was only by a factor 2. No 
significant difference was measured between ILK WT mice and ILK hetero mice and between 
ILK WT mice and ILK KO mice. ILK KO mice displayed during the first 28 days after the 
primary immunisation the lowest level of IgG, but the IgG production seemed to be very 
potently induced after reboost on day 28 hereby reaching similar levels as the ILK hetero 
mice. On days 35 and 42 there was no significant difference in IgG level between the three 
groups of mice. In the second experiment (right graphic), lower IgG values were measured 
compared to the first experiment. Here, ILK KO mice had the highest IgG titer after the first 
immunisation and displayed after reboost a strong augmentation in IgG production (day 14: 
ILK KO mice versus ILK WT mice, p = 0.0270, and ILK KO mice versus ILK hetero mice, p 
= 0.0300; day 21: ILK KO mice versus ILK WT mice, p = 0.0416, and ILK KO mice versus 
ILK hetero mice, p = 0.0202). 
 
Days after TNP-BSA stimulation
Ig
G
ti
te
r * ** ***
Days after TNP-BSA stimulation
Ig
G
ti
te
r * **
 
74 ILK as a candidate B cell target 
 
Figure 5.9. IgM production in mice with B cell-specific ILK deletion after TNP-BSA immunisation. Graphics 
display data of two independently performed experiments. The level of IgM was measured over time in the sera 
of ILK WT mice (blue, 8 mice), ILK hetero mice (green, 6 mice) and ILK KO mice (red, 8 mice). TNP-BSA 
challenges are indicated with reversed orange triangles. 
 
Regarding IgM production (Figure 5.9), the results of the two tests were more similar. TNP-
BSA gave low IgM levels in all three groups of mice. In the first experiment (left graphic), 
ILK WT mice showed higher values of IgM in their sera after reboost than ILK KO mice and 
ILK hetero mice (day 42, p = 0.0198), but that was not reproduced in the second experiment 
(right graphic) in which the three groups of mice showed more comparable, but low values. 
In a following in vivo experiment, ILK WT, ILK hetero and ILK KO mice were immunised 
with TNP-Ficoll and the production of IgM was followed over time. The production of IgM 
was more potently induced by TNP-Ficoll, reaching a peak at 5 days after the immunisation 
and showing a diminution afterwards (Figure 5.10). 
 
 
Figure 5.10. IgM production in mice with B cell-specific ILK deletion after TNP-Ficoll immunisation. IgM 
production was measured over time in the sera of ILK WT mice (blue, 6 mice), ILK hetero mice (green, 4 mice) 
and ILK KO mice (red, 6 mice) after immunisation with TNP-Ficoll. 
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The ILK KO mice had the highest IgM titer of the three groups and that remained over time 
more or less at the same high level as on day 5. ILK WT mice displayed the lowest level of 
IgM and ILK hetero mice had an IgM titer between the two other groups. ILK KO mice 
differed significantly in IgM titer with ILK WT mice on days 5, 14 and 21 (p = 0.0260, p = 
0.0117 and p = 0.0014, respectively), but not with ILK hetero mice. 
5.3.2.4. Deletion of ILK has no significant impact on the anti-BHK-570 
xeno-antibody production 
In the previous in vivo experiments, mice were immunised with a TNP-hapten conjugate to 
induce Ig-production. Here, we examined if the B cell-specific deletion of ILK might affect 
the IgG and IgM production against baby hamster kidney cells BHK-570. 
 
Figure 5.11. Xeno-antibody production in mice with B cell-specific ILK deletion against BHK-570 cells. IgG 
(A) and IgM (B) production was measured by flow cytometry in the sera of ILK WT mice (blue, 3 mice), ILK 
hetero mice (green, 3 mice) and ILK KO mice (red, 3 mice) after immunisation with BHK-570 cells (orange 
reversed triangle). 
 
The production of IgG against BHK-570 (Figure 5.11 A) was potently induced and the level 
of IgG was very similar in the three groups. Thus, lowering or deletion of ILK expression did 
not affect the xeno-IgG production. The level of IgM against BHK-570 (Figure 5.11 B) was 
less strongly up-regulated compared to IgG, but there was some more divergence between the 
three groups. ILK hetero mice showed a higher level of IgM in their sera compared to ILK 
WT and ILK KO mice, but the difference was not statistically significant due to quite big 
variation in values between the 3 ILK hetero mice. Experiment has been performed only one 
time. 
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5.3.2.5. In vitro splenic B cell activation experiments 
In previous in vivo experiments, alterations in IgG, IgM, IL6 and TNFα were investigated in 
the peripheral blood. Subsequently, we examined if the deletion of ILK might have a more 
profound effect on the activity of splenic B lymphocytes. Additionally, we investigated if 
there is a difference in the inhibitory action of compound OSU-T315. ODN1826, resiquimod, 
TNP-BSA, TNP-Ficoll and LPS were tested on WT mouse splenic B lymphocytes to see 
which stimulator gave good induction in proliferation and production of IL6 and TNFα. 
Apparently, LPS was the best stimulator, the other stimuli had no or hardly any effect on the 
murine B cells. Splenic B cells of ILK WT, ILK hetero and ILK KO mice underwent 
stimulation with LPS and OSU-T315 was added at different doses. Experiment has been 
performed only one time. 
 
Figure 5.12. Effect of OSU-T315 on the IL6 (A) and TNFα (B) production and the proliferation (C) of splenic B 
cells from ILK WT (blue), ILK hetero (green) and ILK KO (red) mice upon stimulation with LPS. 
 
Generally, the production of IL6 (Figure 5.12 A) and TNFα (Figure 5.12 B) and the B cell 
proliferation (Figure 5.12 C) were not substantially altered by a lowered or deleted expression 
of ILK in the B lymphocytes. OSU-T315 strongly lowered the proliferation (IC50 µM: ILK 
WT = 0.227; ILK hetero = 0.143; ILK KO = 0.103) and the secretion of IL6 (IC50 µM: ILK 
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WT = 0.081; ILK hetero = 0.055; ILK KO = 0.059) and TNFα (IC50 µM: ILK WT = 0.469; 
ILK hetero = 0.485; ILK KO = 0.686), but there was no considerable difference in potency of 
the compound between the three groups of mice. 
5.3.2.6. Deletion of ILK possibly gives a higher sensitivity to LPS-
induced septic shock 
We investigated if mice with a lowered or completely deleted expression of ILK in B 
lymphocytes were more sensitive to LPS-induced sepsis (Figure 5.13). 
 
Figure 5.13. LPS survival assay. ILK WT mice (blue), ILK hetero mice (green) and ILK KO mice (red) were 
challenged by 2 different doses of LPS (100 µg, long dashed line; 300 µg, solid line) and were followed up 
during 7 days. Eight mice were used per tested dose of LPS. 
 
At dose 300 µg of LPS, ILK KO mice seemed to have a higher lethality rate than ILK WT 
mice and ILK hetero mice, however, it is not decisive to say that the deletion of ILK in B 
lymphocytes makes mice more vulnerable to LPS-induced septic shock. 
 
All obtained in vitro and in vivo ILK data are brought together in table 5.1 on the next page.
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ILK inhibition Species Experimental condition Read-out Results 
  In vitro 
/in vivo 
Cell type or  
treatment in vivo 
Stimulus   
OSU-T315 Human In vitro Namalwa ODN2006 CD markers IC50: CD40 = 270; CD69 = 630; CD70 = 740; CD80 = 240; CD83 = 620; CD86 = 300  
     WST-1 IC50: 4 600  
   Primary B cells ODN2006 CD markers IC50: CD40 = 490; CD69 = 274; CD70 = 454; CD80 = 527; CD83 = 726; CD86 = 459  
     IgG and IgM IC50: IgG = 205; IgM = 510  
     IL6 IC50: 555  
     Proliferation IC50: 415  
    Resiquimod IgG and IgM IC50: IgG = 260; IgM = 365  
     IL6 IC50: 1 095  
     Proliferation IC50:  3 000  
    TNP-BSA IgG and IgM IC50: IgG = 985; IgM = 965  
     IL6 IC50: 1 505  
     Proliferation IC50: 650  
 Mouse In vivo Oral treatment OSU-T315 
after stimulation 
ODN1826 IL6 
TNFα 
IL6 , but no dose-dependent effect 
TNFα remained unaltered  
Genetic KO  Mouse In vivo Stimulation ODN1826 IL6 and TNFα No difference between WT mice and mice with ILK KO  
in CD19+ cells    TNP-BSA IgG and IgM No difference between WT mice and mice with ILK KO  
    TNP-Ficoll IgM No difference between WT mice and mice with ILK KO  
    BHK-570 Xeno-IgG and IgM No difference in xeno-Ab production between WT mice and mice with ILK KO  
   Septic shock induction LPS Survival rate Survival rate was similar between WT mice and mice with ILK KO  
Genetic KO  
in CD19+ cells  
Mouse In vitro Splenic B cells LPS IL6 and TNFα IL6 IC50: ILK WT = 81, ILK hetero = 55 and ILK KO = 59 
TNFα IC50: ILK WT = 469, ILK hetero = 485 and ILK KO = 686 
and OSU-315     Proliferation Proliferation IC50: ILK WT = 227, ILK hetero = 143 and ILK KO = 103 
Table 5.1. Overview of the obtained in vitro and in vivo ILK data. The measuring unit of the IC50-values is nM. 
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5.4. Discussion 
Based on various in vitro tests on the human Namalwa B cell line and on human primary B 
cells using different techniques (shRNA-mediated deletion or small molecule inhibitor), it 
was shown that ILK may be important for B lymphocyte immune activation by various 
stimuli such as ODN2006, resiquimod and TNP-BSA. Indeed, inactivation or inhibition of 
ILK suppressed several in vitro B lymphocyte responses (such as CD69, CD70, CD80 and 
CD86 expression, IgG, IgM or IL6 production as well as proliferation). The potency of ILK 
inhibitor OSU-T315 was validated by IC50 values of generally 0.5 µM. 
When investigated in vivo in mice, OSU-T315 treatment resulted in significant suppression of 
ODN1826-induced IL6 production, however, a clear dose response effect could not be 
demonstrated. In vivo production of TNFα was not affected by OSU-T315 treatment. 
Unfortunately, none of the stimuli used on human B cells gave an adequate activation of 
murine splenic B cells to compare effects of OSU-T315 in comparable models. To know if 
ILK blockade may work in vivo and not only in vitro as shown in the shRNA experiments, we 
created mice with B cell-specific ILK KO. In these mice and using various B cell stimulation 
experiments, the absence of the ILK gene did not reveal a suppressive effect in various B cell 
phenomena such as ODN1826-induced IL6 or TNFα production (but as proven in vivo with B 
cell-deficient mice, IL6 and TNFα are not exclusively produced by B lymphocytes), TNP-
BSA- or TNP-Ficoll-induced IgG or IgM production and xeno-antibody production. When 
using B cells from these mice in vitro, there were no defects shown either. The latter may 
suggest that the role of ILK in human and murine B cells is not fully overlapping and needs 
deeper investigation to clarify its role and to check if mice are an acceptable model to study B 
cell biology. This is further supported by the fact that the stimuli we used in the present study 
to stimulate human B cells in vitro do not work in mice and, vice versa those used in mice do 
not work in humans. Another possible explanation could be that the deletion of a target can 
induce an alternative “rescue”-pathway to compensate for the absence of the target and that 
could have happened in our ILK KO mice. 
Small molecule OSU-T315, which is modelled from the scaffold that docks into AKT-binding 
site of ILK, was originally designed to specifically disrupt the interaction of AKT with its 
binding site on ILK
217
. For complete activation, AKT needs to be phosphorylated on Thr-308 
by PDK1 and on Ser-473 by PDK2. The identity of PDK2 has been elusive for quite a while 
and ILK was regarded as a putative PDK2
217
. In literature, western blot analysis on the 
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phosphorylation of AKT on Ser-473 versus Thr-308 in PC-3 cells, a human prostate cancer 
cell line, and in MDA-MB-231 cells, a human breast cancer cell line, demonstrated that OSU-
T315 selectively suppressed AKT phosphorylation on Ser-473, not on Thr-308, in a dose-
dependent manner and this was accompanied by parallel decreases in the phosphorylation 
levels of GSK3β and MLC, two downstream targets of ILK207. As a positive control, shRNA-
mediated KO of ILK in PC-3 cells modulated the phosphorylation of these signalling proteins 
in a manner similar to that of OSU-T315
207
. Together, the findings suggested that OSU-T315 
might mediate Ser-473 AKT dephosphorylation through inhibition of ILK or through 
interaction with ILK. However, the mTORC2 complex, composed of mTOR, Rictor, and 
Sin1, has now been reckoned as PDK2 and not ILK
218,219
. In particular, Rictor, which 
interacts directly with ILK, facilitates the phosphorylation of AKT by ILK
218,220,221
. 
Very recently, a novel mechanism of action of OSU-T315 was characterized in studies on 
survival and proliferation pathways in human CLL. OSU-T315, which showed a preferential 
cytotoxicity toward CLL cells compared with normal B and T cells, inhibited AKT signalling 
independently of ILK by preventing the translocation of AKT to lipid rafts
217
 which are 
specialized membrane micro-domains for the interactions and regulations of membrane-
localized kinases. The activation of the PI3K/AKT pathways initiates at the plasma membrane 
where PIP3 recruits AKT to lipid rafts near the plasma membrane, leading to its subsequent 
phosphorylation and activation by PDK1 and PDK2. OSU-T315 displaced AKT from lipid 
rafts and impaired in that manner the AKT phosphorylation induced by a variety of signalling 
pathways including BCR, CD40L, TLR9 and integrin, and not through inhibition of ILK as 
expected
217
. This could imply that our obtained phenotypic outcomes in the in vitro and in 
vivo experiments with OSU-T315 may rather be the result of off-target effects. In the in vitro 
experiment with LPS-stimulated murine B cells, OSU-T315 displayed a similar potency in 
lowering proliferation and secretion of IL6 and TNFα between ILK WT, ILK hetero and ILK 
KO mice, supporting the hypothesis that OSU-T315 has other actions besides blocking ILK. 
Since ILK is an evolutionarily conserved and ubiquitously expressed protein, there are many 
studies performed on complete or conditional deletion of ILK in various organisms and cells 
to find out more about its functions. A complete deletion of ILK leads to lethality in mice
200
, 
Xenopus laevis
222
, Drosophila flies
223
 and Caenorhabditis elegans worms
224
. Using the 
Cre/loxP recombination system, the mouse ILK-encoding gene has been deleted in several 
cell types and organs (fibroblasts
200
, immortalized macrophages
203
, vascular endothelial 
cells
225
, vascular smooth muscle cells
226
, chondrocytes
227
, heart
228
, mammary epithelial 
cells
229
). One mouse model described the phenotype of a T cell-specific deletion of ILK, Lck-
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Cre
+ 
/ ILK
flox/flox
 mice
204
. These mice showed neither gross developmental abnormalities nor 
thymus defects. Thymocytes from the T cell-specific ILK KO mice were phenotypically 
indistinguishable from control WT thymocytes, but there was enhanced susceptibility to cell 
death upon stress conditions like serum deprivation. ILK-deficient T cells showed an aberrant 
response to the chemokines CXCL12 and CCL19, indicating that ILK might have a role in 
leukocyte chemotaxis and immune cell trafficking. But ILK deletion did not affect T cell 
proliferation. Normal numbers and proportions of CD4
+
 and CD8
+
 peripheral T cells were 
observed in the mice with T cell-specific deletion of ILK. These observations seem to be 
compatible with our earlier data describing rather weak effect of compound OSU-T315 in 
MLR (Table 4.1). 
In conclusion, we wanted to investigate if ILK would prove value as B cell target for 
treatment of (B cell-related) immunological disorders and pathologies. The human in vitro 
experimental data gave a first impression of ILK as being a central target for interference in 
different B cell signalling pathways and formed the onset of in vivo investigations about ILK 
in the immunology. However, with the obtained murine in vivo and in vitro data, it is likely 
that small molecule OSU-T315 might have another way of action than inhibiting ILK and 
that, under the tested conditions, ILK might not play a notable role in B cell activity. 
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Chapter 6 : General discussion and future perspectives 
As increasing knowledge is gathered about the pathology of diseases, there is, as a 
consequence, an increasing demand for more specific, effective and affordable drugs to deal 
with the anomalies in the immune responses while leaving the normal responses undisturbed. 
In reality, however, there is a steep decline in the approval rate for novel molecular entities. 
The rate of attrition, as drug-candidates move through clinical trials, is still critically high and 
can be partly attributed to the disconnection between human physiology and the in vitro 
screening regimen which is usually at the beginning of the drug development chain. T cells 
have long been considered as main targets for the treatment of immune disorders and the 
majority of marketed immunomodulators are directed towards T cells. In this work, we 
contributed to the field of drug discovery by establishing an in vitro screening assay for the 
identification of (new) B cell-specific targets that would be valuable in the development of 
urgently needed innovative (small molecule) medicine for treatment of immune disorders and 
transplant rejection. 
 
Strategies to identify potential drug candidates are diverse in approach and all have their 
strengths and weaknesses. For the set up of our in vitro screening assay, we had to consider all 
together several pragmatic issues, including: first line screening assay, possibility to 
automation, costs, time span of the assay, a clear and manageable protocol, robustness and 
reproducibility, etc. We went for the idea of a first line screening assay with a multiplexed 
read-out to characterize best the hits after the first screening. Further, we needed to decide 
what has to be screened: a chemical library of small molecule agents to identify lead 
molecules with modulatory effects on B cells or a siRNA library to identify (new) relevant B 
cell targets. The strength of siRNA is that it interferes efficiently with the expression of 
specific genes with limited off-target effects in opposite to small molecules of a chemical 
library which are rarely well-characterized in specificity and potency. The choice for 
screening a siRNA library, consequently, implied that we had to look for a human B cell line 
that is susceptible to siRNA transfection because primary cells are very difficult to transfect. 
Above all, the human B cell line had to serve as a reliable substitute for the primary B cell. 
Nonetheless, the use of a cell line is more appropriate to ensure robustness, reproducibility 
and continuity of the screening as cell lines are more homogeneous and they are easy to 
cultivate allowing collection of large amounts of cells. The B cell‟s versatility of actions and 
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its ability to adapt in response to changes in the (micro-) environment make the process of B 
cell-specific drug discovery challenging. There is a plethora of in vitro stimulatory conditions 
for human B lymphocytes described in literature, ranging from a single agent stimulator to 
complex stimulator-mixtures, each inducing different responses. To maintain as best as 
possible the robustness and reproducibility of the screening, we screened various elementary 
B cell stimulators on human polyclonal B cells. TLR9-agonist ODN2006 appeared to have the 
most extensive stimulatory effect on the human B cells. Since cancerous B cell lines 
frequently display abnormal Ig and cytokine production, we focussed on the expression of cell 
surface markers to find a stable substitute for primary B cells. Almost all investigated cell 
surface markers were receptors with a considerable role in B cell activation, because we 
searched for targets involved in activation pathways for the development of drugs that can 
modulate B cell‟s effector functions. Human Burkitt‟s lymphoma Namalwa displayed a 
dynamic immunophenotypic profile upon ODN2006 stimulation with a close resemblance to 
that of human B lymphocytes. For read out of the screening, we focussed on the expression of 
cell surface markers CD70 and CD80, because the signalling pathways of these two markers 
are partially overlapping and partially divergent. That would permit us to detect for common, 
possibly proximal targets in CD70 and CD80 signalling and for more distal, divergent targets 
in either CD70 signalling or in CD80 signalling.  
 
To detect (new) B cell targets with the siRNA screening, we first focussed on protein kinases 
because they are important mediators of signalling cascades for the regulation of the cell‟s 
metabolism and their catalytic activity can be manipulated by pharmacological drugs. Other 
appealing drug targets include lipid kinases, phosphatases, esterases, proteases, ion channels, 
receptors (G protein-coupled receptors, nuclear hormone receptors), structural proteins, 
membrane transport proteins and nucleic acids. 
Via screening of the lentiviral shRNA human kinase library, we have identified several lethal 
kinases causing cell death when deleted in expression and various non-lethal kinases with 
suppressive effect on the up-regulation in expression of CD70, CD80 or both markers. 
Twenty-two kinases affected the expression of both CD70 and CD80 and we focussed first on 
these “candidate target” kinases in order to possibly hit more different pathways and as such 
yield broader biological effects. For 6 “candidate target” kinases, there was a known chemical 
inhibitor available and these inhibitors were analysed in several in vitro functional assays. 
OSU-T315, compound described as inhibitor of ILK, potently suppressed the up-regulation in 
expression of both CD70 and CD80 on Namalwa cells after ODN2006 stimulation and 
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showed in vitro potential as a suppressor of human B cell activity. OSU-T315 actively 
lowered the in vivo IL6-production in common C57Bl6 mice upon TLR9-mediated 
immunisation, but a dose response effect was not observed as seen in vitro with human B 
cells. Although the data from in vivo experimentation with OSU-T315 are quite limited, it 
would be interesting to test OSU-T315 out in preclinical models, such as for RA (collagen-
induced arthritis mouse model), MS (experimental autoimmune encephalomyelitis mouse 
model) or SLE, to see if it has a therapeutic effect. As there was only a limited stock available 
of the compound, we could not execute in vivo experiments at long(er) term to investigate, for 
instance, the effects of OSU-T315 on Ig production and to evaluate its mechanism of action, 
the pharmacokinetic and pharmacodynamic properties and possible toxic side-effects. 
We have successfully generated mice with specific deletion of ILK in B lymphocytes. Our 
goal with this strain was to gain insight about the relevance of ILK in the actions of B 
lymphocytes within a whole, living organism. Throughout all performed experiments with 
ILK KO mice, the deletion of ILK did not produce B cell-modulating effects similar to those 
observed with OSU-T315 in vivo and in vitro on human B cells. The discrepancy can be 
explained by the fact that inhibition of a target by means of drugs is not exactly the same as 
by specific genetic KO. Off-target effects, pharmacokinetic and pharmacodynamic 
characteristics of small molecule agents can give differences in phenotypic outcome, 
especially in vivo in a whole organism. On the other hand, depletion of a target by means of 
genetic deletion can induce an alternative “rescue”-pathway to compensate for the absence of 
the target. Although the data are not yet complete to cover the whole story of ILK and there 
are differences between in vitro and in vivo studies and between human and mouse, we can 
say, based on our obtained data with the ILK KO mice, that ILK may not play an important 
role in B lymphocyte activity. Or perhaps ILK is not a valid B cell target in mice and other 
than mouse experiments need to be executed to investigate if ILK blockade may work in 
humans in vivo. Indications of possible side-effects or other actions of OSU-T315 besides 
blocking of ILK came from the in vitro experiment with LPS-stimulated splenic murine B 
cells wherein it was observed that the inhibitory activity of OSU-T315 on the proliferation 
and the production of IL6 and TNFα did not differ between ILK WT mice, ILK heterozygote 
mice and ILK KO mice. Exploration of the mechanism of action of OSU-T315 on the B cell 
would be interesting to understand its specific target. 
 
Because of the promising data that OSU-T315 gave in the in vitro functional assays, our focus 
in this work went to its target ILK. The atypical catalytic domain of ILK may be 
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advantageous and prove value for the development of more specific drugs, because most of 
the described protein kinase inhibitors are directed to the ATP-binding site within the catalytic 
domain which is strongly conserved in the human kinome. The high degree of homology 
between protein kinase family members and, additionally, the required high affinities of the 
inhibitors to compete with the high in vivo ATP concentrations leads to a high prevalence of 
secondary target effects
178,230,231
. Most inhibitors have the potential to inhibit multiple targets 
(e.g. dasatinib). There is increasing interest in identifying kinase inhibitors that do not 
compete with ATP. 
In earlier studies, ILK was investigated in various organisms and many cell types, but it was 
not yet studied in B cells. Our work provides first data about ILK in the context of B cells. 
 
The screening of the lentiviral shRNA library resulted in a first categorization of the human 
protein kinases. A first subdivision is in lethal kinases and non-lethal kinases and the non-
lethal kinases can be further categorized in kinases that can suppress either CD70 or CD80, 
kinases that can suppress both CD70 and CD80 and kinases that have no effect at all. The 
listing of the kinases for each category was not given for intellectual property reasons. As 
mentioned earlier, for only a few “candidate target” kinases there was a chemical inhibitor 
available. So, most kinases from that group could not be further examined for their potential 
as B cell target through chemical inhibition. The CRISPR/Cas9 technology, which stands for 
„Clustered Regularly Interspaced Short Palindromic Repeats‟ and „CRISPR-associated 
nuclease 9‟232, is a quite new tool for targeted genome editing and can provide the solution. 
Currently, the CRISPR/Cas9 system is regarded as the simplest (making it faster and more 
cost effective), most versatile and precise method of genetic manipulation with a wide range 
of applications in many cell lines, organisms and even primary cells and basically consists of 
two key molecules that introduce a change into DNA: the enzyme Cas9, which acts as a pair 
of “molecular scissors” that can cut the 2 strands of DNA at a specific location, and a piece of 
RNA, called guide RNA (gRNA), that „guides‟ Cas9 to the right part of the genome233. 
Several huge gRNA libraries have already been created, indicating that the technology is 
gaining a prominent position in genome engineering. Hence, genetic screening of human B 
cells by means of the CRISPR/Cas9 technology might be the way to explore further and more 
profoundly on the role and function of our “candidate target” kinases in human B cell 
activation. This research can be extended to the other kinase groups (CD70 only, CD80 only 
and lethal) to obtain a sub-categorization of the kinases. 
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Also interesting for further refinement of the protein kinase groups would be the use of other 
read-out parameters. In the discussion of Chapter 4, we postulated a correlation between IgG 
production and expression of CD86. Maybe CD86 can be a more sensitive parameter to detect 
targets with a preferably B cell modulatory activity. Unfortunately, the Namalwa cell line is 
incapable to produce IgG, so the proposed CD86-IgG parallel cannot be explored in more 
detail by means of the shRNA library screening on Namalwa. Screening on inhibitory 
receptors can provide more information about the regulatory pathways of B cell activity with 
the idea of favouring expansion, development and activation of Bregs instead of inhibiting 
activated effector B cells and that could be an elegant way to control B cell activity in 
pathological conditions. CD22, CD32b and CD72 act as negative regulators of BCR 
signalling and hold great potential for therapy of AIDs and for treatment in organ 
transplantation. CD22, also known as Siglec-2, is a member of the sialic acid-binding 
immunoglobulin-like lectin (Siglec) family
162
 and is exclusively expressed on mature B cells 
and to a lesser extent on some immature B cells. The humanized monoclonal anti-CD22 
antibody epratuzumab is subject of various clinical trials for the treatment of moderate-to-
severe SLE
162,234
. Apparently, binding of epratuzumab induces co-localization of CD22 with 
the BCR, independent of BCR engagement, hereby promoting the inhibitory function of 
CD22 on BCR-mediated signalling and thereby modulating B cell activity with inhibition of 
B cell activation, but without total B cell depletion
106
. CD32b or FcγRIIB is expressed on B 
cells, plasmablasts and long-lived PCs and is the sole inhibitory member of the FcγR family 
with an important role in the down-regulation of Ab-production
102
. It is noticed that B cells 
from SLE patients have either a lower expression of CD32b or they express a dysfunctional 
form of the receptor at an increased frequency
102,103,105
. CD72 was quite recently identified as 
an inhibitory receptor that is dominantly expressed in B cells
102
. CD72-deficient mice 
spontaneously develop SLE-like disease (production of autoAbs to various nuclear 
components and development of immune complex nephritis) and CD72 polymorphism is 
strongly associated with human SLE, hence, making CD72 a novel meaningful target in the 
treatment of SLE
162
. The quite unfamiliar CD83 is assumed to be an inhibitory receptor and 
has gained attention for investigations in B cells and T cells to further explore its mechanism 
of action for immune regulation. Just like CD22, CD83 is a member of the Siglec-family
235
. 
Hence, it can be very interesting to see if a deletion of a protein kinase or other target would 
increase or further decrease the expression of inhibitory receptors, such as CD22, CD32b, 
CD72 and CD83, indicating a more regulatory status or a hyper-active status, respectively. 
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Counter-screen(s) on human cell lines derived from non-B cells, for instance T cells, 
macrophages and dendritic cells, upon appropriate stimulatory conditions and with relevant 
read-out parameters can further determine the B cell specificity of the identified protein 
kinases. The group of “lethal” kinases should be included in the additional (counter-) screens 
to reveal new B cell (or even malignancy)-specific targets. 
 
Full exploitation of our developed screening assay can lead to the identification of B cell 
targets that, consequently, stimulate the development of original drugs. 
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Chapter 7 Summary 
It becomes more and more clear that B lymphocytes play an important pathogenic role in 
various immune mediated disorders as well as in transplant rejection. Still to date, there are 
not many B cell-specific immunosuppressive drugs available. 
The present study was undertaken first, to identify an in vitro B lymphocyte stimulation assay 
able to optimally and most broadly reproduce polyclonal human B cell biology and, next, to 
use it to detect new B lymphocyte specific targets allowing for the discovery of new B 
lymphocyte specific small molecule drugs. 
From 13 different known in vitro B cell stimuli, it was found that stimulation with the TLR9-
agonist ODN2006 resulted in the clearest and most broad in vitro activation of polyclonal 
human B cells as measured with various criteria. Human Burkitt‟s lymphoma Namalwa was 
selected as a more homogeneous substitute for primary B cell and the expression of cell 
surface markers CD70 and CD80 was chosen as read-out. 
Next the ODN2006/Namalwa assay was used to identify potential, new B lymphocyte drug 
targets by selectively eliminating 501 different human protein kinases using a lentiviral 
library carrying interfering RNA able to functionally "knock-out" the various protein kinases 
in the Namalwa cells. The whole screening identified 60 protein kinases involved either in the 
CD70 pathway or in the CD80 pathway as well as 22 other kinases suppressing both cell 
surface marker pathways. From none of the latter 22 kinases, a role in B cell activation has 
been described until today. For only 6 of them, a small molecule inhibitor of the respective 
kinase activity was available, but only one of these compounds showed significant in vitro 
effects on the activation of Namalwa cells as well as of polyclonal human B cells. OSU-T315 
showed potential as suppressor of human B cell activity and, hence, the focus was laid on this 
compound and its target ILK.  
Mice with B cell-specific ILK depletion have been successfully generated and were of great 
value for investigating the role and function of ILK in the B cell biology of the living 
organism. The exploratory in vivo knock-out experiments may not have confirmed ILK‟s 
potential function in B cell activation, but can motivate for further investigation of ILK and of 
all the other categorized kinases. Exploration of the “candidate target” shortlist is still 
ongoing. 
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Chapter 8 Samenvatting 
Het wordt meer en meer duidelijk dat B lymphocyten een belangrijke rol hebben in de 
pathogenese van verscheidene immuunziekten en in de afstoting van getransplanteerde 
organen. En toch, tot op heden zijn er maar een beperkt aantal immunosuppressiva 
beschikbaar die gericht zijn op de B lymphocyten. 
Deze studie was ondernomen, ten eerste, om een in vitro B lymphocyte stimulatie-test te 
vinden die zo optimaal en ruim mogelijk de biologie van polyclonale humane B cellen 
weergeeft en, vervolgens, om deze stimulatie-test te gebruiken voor detectie van nieuwe B 
cel-specifieke doelwitten die kunnen bijdragen tot de ontdekking van nieuwe B cel-specifieke, 
moleculaire geneesmiddelen. 
Van 13 verschillende in vitro B cel stimuli bleek stimulatie met de TLR9-agonist ODN2006 
te resulteren in de meest uitgesproken en meest algemene in vitro activering van polyclonale 
humane B cellen zoals het was gemeten met verscheidene criteria. Humane Burkitt‟s 
lymphoma Namalwa was geselecteerd als meer homogene vervanger van de primaire B cel en 
de expressie van celoppervlakte merkers CD70 en CD80 was gekozen als read-out. 
Vervolgens werd de ODN2006/Namalwa test gebruikt om potentiële, nieuwe B lymphocyte 
drug doelwitten te identificeren door 501 verschillende humane proteïne kinasen selectief uit 
te schakelen in de Namalwa cellen met behulp van een heuse bibliotheek van lentivirale 
partikels met interfererende RNA moleculen. Het screenen van de hele bibliotheek 
identificeerde 60 proteïne kinasen die betrokken zijn in ofwel de CD70 pathway ofwel in de 
CD80 pathway, maar ook 22 proteïne kinasen die beide celoppervlakte merkers onderdrukten. 
Van die laatst genoemde 22 kinasen was er tot dan toe geen rol in de B cel activering 
beschreven. Voor 6 kinasen was er een klein moleculaire inhibitor beschikbaar, maar slechts 
één van deze inhibitoren beïnvloedde aanzienlijk de in vitro activering van zowel Namalwa 
cellen als polyclonale humane B cellen. OSU-T315 toonde potentieel als onderdukker van 
humane B cel activiteit en, aldus, de aandacht werd gevestigd op deze inhibitor en zijn 
doelwit ILK.  
Muizen met een B cel-specifieke uitschakeling van ILK werden succesvol gecreëerd en waren 
waardevol voor het onderzoek naar de rol en functie van ILK in de B cel biologie van het 
levend organisme. De explorerende in vivo knock-out experimenten hebben misschien niet de 
potentiële functie van ILK in de B cel activering geverifieerd, maar kunnen de motivatie 
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vormen voor verdere exploratie van ILK en van al de andere gecategoriseerde kinasen. Het 
onderzoek van de “kandidaat doelwit” lijst is lopende. 
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